

Bobby Jindal
GOVERNOR



Alan Levine
SECRETARY

State of Louisiana
Department of Health and Hospitals
Office of the Secretary

May 18, 2010

The Honorable Bobby Jindal
Governor, State of Louisiana
P.O. Box 94004, Capitol Station
Baton Rouge, LA 70804-4004

The Honorable Joel T. Chaisson, II, President
Louisiana State Senate
P.O. Box 94183, Capitol Station
Baton Rouge, LA 70804-9183

The Honorable Jim Tucker, Speaker
Louisiana State House of Representatives
P.O. Box 94062, Capitol Station
Baton Rouge, LA 70804-9062

Dear Governor Jindal, President Chaisson, and Speaker Tucker:

In response to Senate Bill No. 689 of the 2004 Regular Session and House Bill No. 369 of the 2005 Regular Session, the Louisiana Department of Health and Hospitals (DHH) submits the enclosed report. These bills require DHH to provide an annual written report to the governor and to the legislature regarding the cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds returned to the federal government related to pharmaceutical rebates, and an analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list.

The bureau of health services financing (Medicaid) within DHH is available to discuss the enclosed report and recommendations with you at your convenience. Please contact M.J. Terrebone, pharmacy director, at (225) 342-9768 with any questions or comments you may have.

Sincerely,

Alan Levine
Secretary

Enclosures

Cc: Senator Lydia Jackson
Senator Willie L. Mount
Representative Kay Katz
David R. Poynter Legislative Research Library

PREFERRED DRUG LIST (PDL)

REPORT PREPARED IN RESPONSE TO -
SENATE BILL NO. 689 (ACT 705) OF THE 2004
REGULAR SESSION AND HOUSE BILL NO.
369 (ACT 177) OF THE 2005 REGULAR
SESSION

MAY 2010

Contact:

Louisiana Department of Health and Hospitals
M. J. Terrebonne
Bureau of Health Services Financing
628 North 4th St. – 7th Floor, Baton Rouge, LA 70802
(225) 342-9768
MJTERREBONNE@LA.GOV

EXECUTIVE SUMMARY

Act 395 of the 2001 Regular Session of the Louisiana Legislature amended R.S.46:153.3 (B)(2)(a) and authorized the Department of Health and Hospitals (DHH) to establish a drug formulary utilizing a prior approval process or any other process or combination of processes that prove to be cost-effective in the medical assistance program. The Act also created a Pharmaceutical and Therapeutics Committee consisting of 21 members appointed by the Governor. The list of members can be found at www.legis.state.la.us/boards/boardsearch.asp.

The Committee began meeting in August 2001. On June 10, 2002, the Department implemented a preferred drug list (PDL) with a prior authorization (PA) process and a Supplemental Drug Rebate program through a phased-in approach. The PDL/PA process and accompanying supplemental rebate features were implemented meeting all applicable federal and state statutes.

Subsequently, Senate Bill No. 689 (Act 705) of the 2004 Regular Session of the Louisiana Legislature provides each year the department shall provide a written and public report to the legislature and the governor 30 days prior to the regular legislative session. The report shall cover: (i) The cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds, returned to the federal government related to pharmaceutical rebates; and (ii) An analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list (*Appendix 1*).

Act 177 of the 2005 Regular Session further amended the PDL/PA process. R.S.46:153.3(C) added atypical antipsychotic drug class and the immunomodulator and hepatitis C – specific antiviral drug class and required DHH to include data from these classes with the data collected on all drug classes reviewed on the Medicaid PDL for the annual report to the Legislature and Governor (*Appendix 2*).

The program is administered by the Medicaid Pharmacy Benefits Management section of DHH utilizing the services of three contractors: Unisys; the University of Louisiana at Monroe (ULM), School of Pharmacy; and Provider Synergies. The PDL/PA process and supplemental rebate system are now fully operational.

Each prior authorization is given for a specific drug for a specific recipient for a specific period of time. In accordance with state and federal statutes, requests must be acted upon within 24 hours. Also, a minimum of a 72-hour supply of a medication may be obtained without prior authorization in emergency situations.

In SFY 2009, ULM processed approximately 48,423 prior authorization requests monthly. Listings of those drugs which receive prior authorization requests are included in the Preferred Drug List (PDL)/Prior Authorization (PA) list at www.lamedicaid.com and *Appendix 3* of this report. The state received \$37,833,592 in supplemental rebates in SFY 2008 and \$45,635,734 in SFY 2009. Provider Synergies has projected \$38,625,704 in program savings for SFY 2010 resulting from market shift and supplemental rebates. More detailed information regarding the PDL and the financial methodology is available in the *Louisiana Medicaid PDL Program Overview and Results, February 1, 2010* report available at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=2958>.

The foregoing is presented as a brief overview of the prescription limit policy. The following is the report with appropriate appendices.

MEDICAID PHARMACY BENEFITS MANAGEMENT PROGRAM

Background

Prior to 2001 Louisiana had an open formulary law which required Medicaid reimbursement of all FDA approved legend drugs, with a few exemptions. The law also prohibited the use of prior or post-authorizations in the pharmacy program. These laws restricted Louisiana's use of management tools available to other states to control costs.

Act 395 of the 2001 Regular Session of the Louisiana Legislature amended R.S.46:153.3 (B)(2)(a) and eliminated the prohibition of utilizing a prescription prior authorization process within the Louisiana Medicaid Program. The law authorizes the Department of Health and Hospitals (DHH) to "...establish a drug formulary that utilizes a prior approval process or any other process or combination of processes that prove to be cost-effective in the medical assistance program...."

Other provisions of Act 395 and R.S. 46:153.3 are:

- Permits DHH to enter into contractual arrangements to perform the prior approval (PA) functions with a school of medicine, a college of pharmacy, the fiscal intermediary for the Medicaid program, or such other qualified contractors that it deems appropriate, within the scope of the PA mandated provisions of federal law.
- Mandates a maximum 24-hour response time on requests.
- Requires that a 72-hour supply of a medication may be obtained without a prior authorization in emergency situations.
- Creates a Pharmaceutical and Therapeutics Committee comprised of 21 members who are appointed by the Governor and confirmed by the Senate. The list of members can be found at www.legis.state.la.us/boards/boardsearch.asp (Medicaid and Pharmaceutical and Therapeutics Committee).

Subsequently, Senate Bill No. 689 (Act No. 705) of the 2004 Regular Session was passed requesting additional information be reported to the Legislature and the Governor 30 days prior to the regular legislative session (*Appendix 1*). Specifically, the report shall cover: 1) The cost of administering the preferred drug list, including the cost of administering the prior authorization function, the costs of development and maintenance of the preferred drug list and aggregate funds, returned to the federal government related to pharmaceutical rebates; and 2) An analysis of the utilization trends for medical services provided by the state and any correlation to the PDL.

Act 177 (HB 369) of the 2005 Regular Session and Act 107 (HB 680) of the 2007 Regular Session further amended the PDL/PA process (*Appendix 2*). R.S.46:153.3(C) added atypical antipsychotic drug class and the immunomodulator and hepatitis C – specific antiviral drug class and required DHH to include data from these classes with the data collected on all drug classes reviewed on the Medicaid preferred drug list for the annual report to the legislature and governor.

Program Implementation and Operations

On June 10, 2002 DHH implemented a PDL with a PA process and a Supplemental Drug Rebate program through a phased-in approach. The PDL/PA process and accompanying supplemental rebate feature were implemented meeting all applicable federal and state statutes.

The program is administered by the Medicaid Pharmacy Benefits Management section of DHH and utilizes the services of three contractors: Unisys; the University of Louisiana at Monroe (ULM), School of Pharmacy; and Provider Synergies. Services provided by the contractors include:

- Unisys, the Medicaid fiscal intermediary
 - Technology equipment purchase/installation (with ULM) to support the program
 - Application modifications to the current Medicaid Management Information System (MMIS)
 - Design and implement Wide Area Network (WAN) for ULM
 - Creation and support of new web-based pharmacy PA software
 - Implementation of data research applications
 - Design, install and support a data warehouse
 - SAS training for ULM research analysts
 - Training on Pharmacy PA System (DHH and ULM staff)
 - Training prescribers and providers on the PA process
 - Maintain and support PDL/PA and supplemental rebate systems and operations
- University of Louisiana at Monroe (ULM) School of Pharmacy
 - Provide space, staff, and computers
 - Operate pharmacist-staffed PA desk
 - Provide physician consultations
 - Serve as consultants on the Preferred Drug List and Prior Authorization program
 - Perform DHH directed data analysis and outcome studies
- Provider Synergies
 - Secure clinical and costing data for drugs in selected therapeutic classes
 - Perform clinical and economic analysis of manufacturer data
 - Negotiate state supplemental rebates with manufacturers
 - Prepare therapeutic class monographs for Pharmaceutical and Therapeutics Committee deliberations
 - Present clinical and costing data to the Pharmaceutical and Therapeutics Committee

The PDL/PA process and supplemental rebate system are now fully operational. Each prior authorization is given for a specific drug for a specific recipient for a specific period of time. In accordance with state and federal statutes, requests must be acted upon within 24 hours. Also, a minimum of a 72-hour supply of a medication may be obtained without prior authorization in emergency situations.

Under the provisions of R.S.46:153.3 (D), the Louisiana Medicaid Pharmaceutical and Therapeutics Committee was established and began meeting in August 2001. The Committee, comprised of 21 members, including physicians and pharmacists, has met quarterly and is responsible for developing the preferred drug list (PDL) in conjunction with the PA process. The Committee reviews clinical and cost data on various therapeutic classes of drugs for recommendation to DHH for inclusion on the PDL or for review through the prior authorization process.

The PDL is updated bi-annually upon DHH's approval of the Committee's recommendations. The PDL is mailed to prescribers and pharmacists quarterly and is also available on the web at www.lamedicaid.com.

PDL/PA and Supplemental Rebate Impact

The Louisiana DHH contracts with Provider Synergies to negotiate state supplemental rebates with drug manufacturers for the state. Based on these negotiations the state received \$37,833,592 in supplemental rebates in SFY 2008 and \$45,635,734 in SFY 2009. More detailed information is available in Table 1.1. Savings for FY 2009 were approximately \$37,316,515 million. Provider Synergies has projected \$38,625,704 million in program savings for state fiscal year 2010 resulting from market shift and supplemental rebates. The smaller savings estimate is attributable to the new method of calculating and reporting cost avoidance for the program. The information reported in the past was based on 2002 baseline data. The old cost avoidance estimates were based on a comparison of current net-net cost per prescription in 1Q2002 with inflation adjusted prices. Thus, the old report included all cost avoidance measures and drugs that existed since the inception of the program, some which are no longer in existence. It did not include all drugs with supplemental rebates. The new method of deriving cost avoidance compares the cost sheet projections with the PDL results to the actual cost avoidance generated with PDL decision implementation. The detailed explanation can be found in the *2009 Legislative Report on SB 689 and HB369* at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=2363> (Appendix 7, pages 2-4, provides a detailed explanation).

Table 1.1
PDL/PA AND SUPPLEMENTAL REBATE PROGRAM SAVINGS

PROGRAM SAVINGS		
SFY 2008	SFY 2009	SFY 2010
\$98,249,296	\$37,316,515*	\$38,625,704*
SUPPLEMENTAL REBATE		
SFY 2008	SFY 2009	SFY 2010
\$37,833,592	\$45,635,734	\$24,849,450(YTD)**
FEDERAL		
71.78%	71.60%	68.53%
\$27,156,952	\$32,675,186	\$17,029,328 (YTD)**
STATE		
28.22%	28.40%	31.47%
\$10,676,640	\$12,960,548	\$7,820,122 (YTD)**

*The reason for the smaller savings estimate is the method of calculating and reporting cost avoidance for the program has changed. *2009 Legislative Report on SB 689 and HB369* at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=2363> (Appendix 7, pages 2-4, provides a detailed explanation).

**YTD (7/1/2009 – 12/31/2009)

Cost of Prior Authorization (PA) Operations

The Medicaid Pharmacy Benefits Management program utilizes the services of the University of Louisiana at Monroe (ULM) School of Pharmacy, and Provider Synergies for PA operations. Costs for the contractors' services are found in *Table 1.2*.

ULM receives and processes all requests. Listings of those drugs which receive prior authorization requests are available at www.lamedicaid.com and included in *Appendix 3* of this report. Each prior authorization is given for a specific drug for a specific recipient for a specific period of time. In accordance with state and federal statutes, requests must be acted upon within 24 hours. Provisions are in place whereby an emergency override is allowed for a minimum of a 72-hour supply of medicine. During the most recent two quarters the program has averaged approximately 851 emergency overrides. Detailed Emergency Override Report is in *Table 1.3*. ULM processed approximately 774,761 prior authorization transactions in SFY 2009 and approximately 278,643 in SFY 2010 (as of 12/31/09).

Table 1.2
PDL/PA AND SUPPLEMENTAL REBATE CONTRACT COSTS

	Cost	Federal Share 50%	State Share 50%
Pharmacy (PA)	\$574,834	\$287,417	\$287,417
Baseline costs	\$792,312	\$396,156	\$396,156
15% of salaries	146,166	\$73,083	\$73,083
		75%*	25%*
	\$1,851,413	\$1,388,560	\$462,853
TOTAL COSTS	\$3,364,725	\$2,145,216	\$1,219,509
2010			
YTD (7/01/09 thru 12/31/09)			
	Cost	Federal Share 50%	State Share 50%
Pharmacy (PA)	\$286,192	\$143,096	\$143,096
	\$324,996	\$162,498	\$162,498
15% of salaries	\$76,015	\$38,008	\$38,008
		75% *	25% *
	\$869,405	\$652,054	\$217,351
TOTAL COSTS	\$1,556,608	\$995,655	\$560,953

Table 1.3^a
PA Emergency Override Report (Based on RX-M-025, Error Code 487)

Quarter	Number of PA Overrides
October – December 2009	643
July – September 2009	787
April – June 2009	914
January – March 2009	1,051
October – December 2008	880
July – September 2008	561
April – June 2008	1,027
January – March 2008	1,008
October – December 2007	921
July – September 2007	801
April – June 2007	1,002
January – March 2007	1,082
October – December 2006	867
July – September 2006	690
April – June 2006	809
January – March 2006	951
*October – December 2005	4,923
*July – September 2005	887
April – June 2005	660
January – March 2005	696
October – December 2004	842
July – September 2004	947
April – June 2004	1,167
January – March 2004	1,327
October – December 2003	1,353
July – September 2003	1,337
April – June 2003	988
January – March 2003	667
October – December 2002	514
July – September 2002	160

*Prior authorization denial edit temporarily removed due to Hurricane Katrina and Rita.

Analysis of the Utilization Trends for Medical Services and the Preferred Drug List

The Louisiana DHH derives savings from the preferred drug list through supplemental rebates and market shift savings. An analysis of the utilization trends for medical services provided by the state and any correlation to the preferred drug list is provided in the *Louisiana Medicaid Preferred Drug List (PDL) Program Overview and Results February 1, 2010 Provider Synergies report* at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=2958>.

CONCLUSION

The Louisiana Department of Health and Hospitals ((DHH) Preferred Drug List (PDL) continues to be successful. The state received \$37,833,592 in supplemental rebates in SFY 2008 and \$45,635,734 in SFY 2009. Provider Synergies has projected \$38,625,704 in program cost avoidance for SFY 2010 resulting from market shift and supplemental rebates. It is anticipated that the state will continue to realize cost avoidance by continuing to participate in the TOP\$ program and the State Maximum Allowance Cost Program (SMAC).

BIBLIOGRAPHY

Durand, Salter, et.al. (2005). House Bill No. 369 (Act No. 177) of the 2005 Regular Session.

Jackson and Durand (2004). Senate Bill No. 689 (Act No. 705) of the 2004 Regular Session.

Pharmaceutical and Therapeutics Committee List, www.legis.state.la.us/boards/boardsearch.asp

Preferred Drug List (PDL). www.lamedicaid.com

Provider Synergies(2010). "Louisiana Medicaid Preferred Drug List (PDL) Program Overview and Results February 1, 2010. . <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=2958>

Provider Synergies (2009). "Louisiana Medicaid Preferred Drug List (PDL) Program Overview and Results February 13, 2009. *2009 Legislative Report on SB 689 and HB369* at <http://www.dhh.louisiana.gov/offices/publications.asp?ID=134&Detail=2363>

APPENDIX 1

ENROLLED

Regular Session, 2004

ACT No. 705

SENATE BILL NO. 689

BY SENATOR JACKSON AND REPRESENTATIVE DURAND

AN ACT

To amend and reenact R.S. 46:153.3(B)(2)(a)(introductory paragraph) and (b) and to enact
R.S. 46:153.3(B)(2)(e), relative to the medical assistance drug program; to provide
for the utilization of a prior approval process and criteria related thereto; to provide
for rulemaking; to provide for an annual report to the legislature and governor; and
to provide for related matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 46:153.3(B)(2)(a)(introductory paragraph) and (b) are hereby
9 amended and reenacted and R.S. 46:153.3(B)(2)(e) is enacted to read as follows:

13 * * *

[4] B.(1) * * *

(2)(a) The department may establish a drug formulary list that utilizes a prior approval process or any other process or combination of processes that prove to be cost-effective in the medical assistance program. At a minimum any prior approval process shall meet all of the following criteria:

19 * * *

(b) The department may enter into contractual arrangements to perform the prior approval function and the development of the preferred drug list with a Louisiana school of medicine, a Louisiana school of pharmacy, the fiscal intermediary for the Medicaid program, or such other qualified contractor that it

SB NO. 689

ENROLLED

1 deems appropriate. The department may, at the expiration of any current
2 contractual obligation, enter into contractual arrangements through a public
3 request for proposal process to perform the development of the preferred drug
4 list.

5 * * *

6 R.S. 46:153(B)(2)(c) is all new law.

7 (c) Each year the department shall provide a written and public report to the
8 legislature and the governor thirty days prior to the regular legislative session. The
9 report shall cover:

10 (i) The cost of administering the preferred drug list, including the cost of
11 administering the prior authorization function, the costs of development and
12 maintenance of the preferred drug list and aggregate funds, returned to the federal
13 government related to pharmaceutical rebates.

14 (ii) An analysis of the utilization trends for medical services provided by the
15 state and any correlation to the preferred drug list.

16 * * *

PRESIDENT OF THE SENATE

SPEAKER OF THE HOUSE OF REPRESENTATIVES

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____

APPENDIX 2

ENROLLED

Regular Session, 2005

HOUSE BILL NO. 369

BY REPRESENTATIVES DURAND, SALTER, ALARIO, DORSEY, HAMMETT, AND KATZ AND SENATORS HINES, BAJOIE, HEITMEIER, AND MOUNT

ACT No. 177

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

1

AN ACT

2

To amend and reenact R.S. 46:153.3(C), relative to the medical assistance program; to remove certain drugs from the exemptions to the preferred drug list with prior approval; and to provide for related matters.

5

Be it enacted by the Legislature of Louisiana:

6

Section 1. R.S. 46:153.3(C) is hereby amended and reenacted to read as follows:

7

§153.3. Medical vendor reimbursements; allowable restrictions; peer-based prescribing and dispensing practice patterns; Medicaid Pharmaceutical and Therapeutics Committee

10

* * *

11

C.(1) The department shall not restrict by prior authorization; any anti-retroviral prescription drug, included in certain therapeutic drug classes, as prescribed and determined by a prescribing practitioner licensed by the state; to be medically necessary for the treatment and prevention of HIV/AIDS; and schizophrenia or mental illness with psychotic symptoms hepatitis C

16

(2) Therapeutic classes containing prescription drugs which shall be excluded from any prior authorization provisions shall include the following:

18

(a) Anti-retroviral medications, including Such anti-retroviral prescription drugs include but are not limited to protease inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, anti-virals, and fusion inhibitors prescribed for the treatment of HIV/AIDS.

1 (b) Immunomodulators and Hepatitis C-specific antiviral drugs prescribed
2 for the treatment of hepatitis C.

3 (c) Atypical antipsychotic medications prescribed for the treatment of
4 schizophrenia or mental illness with psychotic symptoms:

5 (2) The department shall not restrict by prior authorization an atypical
6 antipsychotic medication prescribed for the treatment of schizophrenia or mental
7 illness with psychotic symptoms for a Medicaid recipient that has had a prescription
8 for such atypical antipsychotic paid for by Medicaid during the six months prior to
9 the effective date of the class being placed on the Medicaid preferred drug list.

10 (3) The department shall not restrict by prior authorization an
11 immunomodulator or hepatitis C-specific antiviral drug prescribed for the treatment
12 of hepatitis C for a Medicaid recipient that has had a prescription for such
13 immunomodulator or hepatitis C – specific antiviral drug paid for by Medicaid
14 during the six months prior to the effective date of the class being placed on the
15 Medicaid preferred drug list.

16 (4) The department shall include data from the atypical antipsychotic drug
17 class and the immunomodulator and hepatitis C – specific antiviral drug class with
18 the data collected on all drug classes reviewed on the Medicaid preferred drug list
19 for the annual report to the legislature and governor as required by Subparagraph (c)
20 of Paragraph (2) of Subsection (B) of this Section.

21 * * *

22 Section 2. R.S. 46:153.3(C) is hereby amended and reenacted to read as follows:

23 §153.3. Medical vendor reimbursements; allowable restrictions; peer-based
24 prescribing and dispensing practice patterns; Medicaid Pharmaceutical and
25 Therapeutics Committee

26 * * *

27 C.(1) The department shall not restrict by prior authorization, any
28 prescription drug, included in certain therapeutic drug classes, as prescribed and
29 determined by a prescribing practitioner licensed by the state, to be medically

1 necessary for the treatment and prevention of HIV/AIDS, hepatitis C, and
2 schizophrenia or mental illness with psychotic symptoms.

3 (2) Therapeutic classes containing prescription drugs which shall be
4 excluded from any prior authorization provisions shall include the following:

5 (a) Anti-retroviral medications, including but not limited to protease
6 inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse
7 transcriptase inhibitors, anti-virals, and fusion inhibitors prescribed for the treatment
8 of HIV/AIDS.

9 (b) Immunomodulators and Hepatitis C-specific antiviral drugs prescribed
10 for the treatment of hepatitis C.

11 (c) Atypical antipsychotic medications prescribed for the treatment of
12 schizophrenia or mental illness with psychotic symptoms.

13 Section 3. Section 1 of this Act shall cease to be effective on June 30, 2007. Section
14 2 of this Act shall become effective June 30, 2007.

15 Section 4. This Act shall become effective upon signature by the governor or, if not
16 signed by the governor, upon expiration of the time for bills to become law without signature
17 by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If
18 vetoed by the governor and subsequently approved by the legislature, this Act shall become
19 effective on the day following such approval.

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____

APPENDIX 3

SCR 54 TRACKING

SPV 2003 - Quarter 4 (July - September 2003)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Expenses Recipient	865,912	779,296	11.1%
	712,846	582,007	22.5%
Total Scripts Paid	3,281,385	2,987,694	9.9%
Total Scripts Paid with PA	11,730	0	
Rx PA Requests Denied	94	0	

Medications

Accutane	Budesonide	Kodien	Percocet 7.5-325MG	Vantin
Action	Cordene SR	Levofloxacin	Plendil	Vascor
Azithrom	Cedax	Lorabid	Pletal	Verelan PM
Actiq	Covera-HS	Mavair Autohaler	Prandin	Vioxx
Achesol	Corzar	Mavall	Priosec	Volmax
Advair Diskus	Darvon-N	Maxair MU	Prazac Weekly	Zantac Effervesce
Aerobid	Deltrol	Mycetex	Pulmicort	Zocor
Aerobid-M	Deltrol LA	Nasacort	Pulmicort Turbuhaler	Zoloft
Allegra	Dihydroet	Nasacort AQ	GV/R	Zydone
Allegra-D	Duoneb	Nasalide	Rhinocort	Zyrtec
Alltree	Dynacirc	Nasarel	Rhinocort Aqua	Zyrtec-D
Alupent	Dynacirc CR	Nexium	Roxicodone	
AmERGE	Eviita	Nimotop	Sorafen	Total Drugs: 97
Alucand	Famvir	Nizatidine	Serevent	
Alucand HCl	Fonase	Noroxin	Serevent Diskus	
Avadate	Fosin	Novac	Sporanox	
Avapro	Glucophage XR	Oxycontin	Teveten	
Avid	Glucovance	PCI	Tizac	
Bacloven	Glyset	Percocet	Volcycle	
Biaxin	Hyzac	Percocet 10-325MG	Vancenase	
Bisolv XL	Imtrex	Percocet 2.5-325MG	Vancort	

To PA Appeals

Inpatient Days	173,080	156,305	10.7%
ER visits	288,104	241,284	19.4%
Physician Visits	732,047	679,900	10.6%
Physicians w/25+ Patients	4,283	4,053	5.7%
Physicians w/50+ Patients	3,155	2,924	7.9%
Specialist Visits	6,266	4,102	2.9%

SCR 54 TRACKING

SYN 2003 - Quarter 2 (October - December 2002)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligible Recipients	801,596	799,787	7.7%
Total Scripts Pdld	757,970	639,452	18.5%
Total Scripts Pdld with PA	3,776,548	3,286,214	14.9%
Rx PA Requests Denied	67,908	11,730	
Rx PA Requests Denied	88	94	
Medications			
Accutane	Doral	Nasacort	Sporanox
Acon	Duoneb	Nasacort AQ	Synagis-DC
Aciphex	Dynacirc	Nasalide	Tilveten
Actiq	Dynacirc CR	Nasarel	Tizoc
Actionel	Evdia	Neum	Vaclyte
Advair Diskus	Famvir	Nimotop	Vancenase AQ
Aerobid	Flovent	Nitrodisc	Vancell
Aerobid-M	Forin	Noroxin	Vantin
Afegrin	Glucophage XR	Novasc	Vascor
Alegra-D	Glucovance	Opium	
Altace	Glyset	Oxitrol	Verelan PM
Alupent	Humalog	Oxycontin	Vlexx
Amerge	Humalog Mix 75/25	PCE	Volmax
Anzemet	Humulin 30/50	Peniac	Zopenex
Aquachloral	Humulin 70/30	Percocet 10-325MG	Zomig Etodolac
Astellin	Humulin L	Percocet 2.5-325MG	Zomig Granules
Atacand	Humulin N	Percocet 7.5-325MG	Zocor
Atacand HCl	Humulin R	Pletal	Zoloft
Atravert	Humulin U	Pindolin	Zydane
Avadale	Hyzor	Priosec	Zyto
Avapro	Imitrex	Protonix	Zytec
Avid	Inderal LA	Provantil Relevebs	Zytec-D
Betapace AF	Kodion	Provigil	
Bisoxin	Kytril	Precoc Weekly	Total Drugs: 135
Bisoxin XL	Lamictil	Pulmicort Turbuhaler	
Capitol w/Codeine	Lantus	QVAR	
Cordene SR	Levoquin	Relenza	
Cedax	Levoflox	Rescal	
Climara	Levorol	Restoril 7.5MG	
Coreg	Lopressor	Rhinocort	
Covera-HS	Lorabid	Rhinocort Aqua	
Czaar	Lumigan	Roxicodone	
Dantrol	Microl Autohaler	Safederm	
Darvan-N	Maxall	Scopace	
Desoxyn	Maxell MLI	Seravent	
Detrol	Maxidone	Seravent Diskus	
Detrol LA	Mentax	Sonata	
Dictionel	Mycatec	Spectazole	

Rx PA Appeals

Inpatient Days	191,270	170,122	12.4%
ER Visits	333,095	266,716	25.9%
Physician Visits	906,657	781,072	16.3%
Physicians w/25+ Patients	4,375	4,121	6.2%
Physicians w/50+ Patients	3,273	2,966	10.4%
Specialist Visits	6,405	4,261	2.3%

SCR 54 TRACKING

SEY 2003 - Quarter 3 (January - March 2003)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles Recipients	880,366	820,445	7.3%
Total Scripts Pd	760,295	664,555	14.4%
Total Scripts Pd with PA	3,483,921	3,442,793	1.2%
Rx PA Requests Denied	96,162	67,908	
	48	68	

Medications

Accutane	Careg	Lontus	Previpac	Zantac ER/dose
Acon	Civera-HS	Levoquin	Prilosec	Zantac Granules
Aciphex	Carboi	Levorotol	Priloxix	Zocor
Aktiq	Daridium	Lemrel	Protopic	Zolam
Activella	Deronan-N	Upilor	Protopic	Zomig
Actionel	Dextol	Loprax	Provigil	Zydane
Acular	Dextol LA	Lorabid	Proloc Weekly	Zytec
Aerobid	Dicronell	Lovenox	Pumicort Respules	Zytec-D
Aerobid-M	Doral	Lunigan	Pumicort Turbulader	
Aktivon	Duoneba	Mazat Autodaler	QVAR	Total Drugs: 156
Allegra	Dynacide	Moxat	Rebil	
Allegra-D	Dynacide CR	Moxat MU	Refexia	
Altace	Evera	Maxidone	Rescula	
Alupent	Famvir	Mentax	Regitil 7.5MG	
Amgenet	Fenoxis	Mycelox	Rhinocort	
Anzemet	Fonase	Nasocut	Rhinocort Aqua	
Arenesp	Foxin	Nasocort AQ	Rowoso	
Aselin	Frova	Nasolide	Roxicodone	
Atacand	Genotropin	Nasoret	Satzen	
Atacand HCT	Glucophage XR	Neatum	Satofem	
Atorvent	Glucovance	Nimrop	Sonata	
Avitale	Glyset	Nitakidine	Spectazole	
Avapro	Humalog	Noroxin	Sporanox	
Avid	Humalog Mix 75/25	Norvatis	Synagis-DC	
Bectoveni	Humotape	Opium	Tasmal	
Betafope AF	Humulin 50/50	Oxitrat	Teveten	
Bladin	Humulin 70/30	Oxycontin	Tizadac	
Bladin XL	Humulin L	PCE	Torecan	
Conas	Humulin N	Pentac	Valcyle	
Capital w/Codeine	Humulin R	Pentost	Vancendao AQ	
Cardene SR	Humulin U	Percocet 10-325MG	Vancett	
Cedax	Hysac	Percocet 2.5-325MG	Vantin	
Climara	Imitrex	Percocet 7.5-325MG	Verelan PM	
Cognex	Indinav LA	Pleial	Vanax	
Colazol	Kodion	Prandin	Volmax	
Combipatch	Kytra	Provachol	Wetchol	
Copaxane	Lomist	Prempro	Xopenex	

Rx PA Appeals

Inpatient Days	189,477	170,520	6.5%
ER visits	172,360	150,609	8.0%
Physician Visits	902,217	879,751	2.6%
Physicians w/25+ Patients	4,224	4,139	2.1%
Physicians w/50+ Patients	3,135	3,014	4.0%
Specialist Visits	6,381	6,215	2.7%

SCR 54 TRACKING

SFY 2003 - Quarter 4 (April - June 2003)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	887,795	640,597	3.6%
Recipients	803,681	682,726	17.7%
Total Scripts Pd/d	3,360,336	3,342,916	0.5%
Total Scripts Pd/d with PA	119,295	96,162	
Rx PA Requests Denied	29	46	

Medications

Accutane	Dantrolen	Unopro	Protonix	Zocor
Action	Darvon-N	Lexotol	Propotic	Zoloft
Aciphex	Dextrol	Uptor	Proventil Repetabs	Zomig
Actiq	Dextro LA	Lopress	Provigil	Zomig MI
Activella	Didronel	Lorabid	Protopic Weekly	Zydone
Acular	Dorol	Lovenox	Pulmicort Turbuhaler	Zyrtec
Acular PF	Duoneb	Lumigan	QVAR	Zyrtec-D
Advair Diskus	Dynacirc	Mosaid Autohaler	Rebil	
Aerobid	Dynacirc CR	Moxidolane	Relenza	Total Drugs: 163
Aerobid-M	Evipla	Mentax	Rescal	
Aldosteron	Famvir	Metoglip	Restinil 7.5MG	
Allergo	Femhrt	Micardis	Rhinocort	
Allergo-D	Flonase	Myclex	Rhinocort Aqua	
Alloro	Flonast	Nasacort	Roxad	
Alupent	Flodin	Nasacort AQ	Ritacidone	
AmERGE	Fortgo	Nasalide	Salean	
Aricept	Frova	Nasarel	Sorafen	
Arzneim	Genotropin	Naxium	Serevent	
Atelkin	Glucophage XR	Nitrolip	Singulair	
Atacand	Glucovance	Nordrapin	Sonora	
Atacand HCT	Glyset	Norexin	Spectozate	
Atrovantil	Humalog	Novacie	Spiranox	
Avadix	Humalog Mix 75/25	Novolog	Symbykos DC	
Avapri	Humotropine	Opium	Tamox	
Avid	Humulin 50/50	Oxitot	Teveten	
Beninc	Humulin 70/30	Oxycontin	Ibuprof	
Betopord AF	Humulin L	Oxyt	Torecan	
Biovin	Humulin N	PCE	Vacetylc	
Cardia	Humulin R	Pendac	Vancendole AQ	
Cordene SR	Humulin U	Pentac	Vanceril	
Cedox	Hyzoor	Percocet 10-325MG	Vantin	
Calera	Imitrex	Percocet 2.5-325MG	Vascor	
Climara	Inderal LA	Percocet 7.5-325MG	Verelan PM	
Cognex	Kadot	Pletal	VETND	
Colazol	Kytril	Prandin	Vloss	
Combipatch	Lamill	Provachol	Volmax	
Coparone	Lantus	Prempro	Welchol	
Covera-HS	Levoquin	Prevprox	Xopenex	
Cotazor	Levator	Prilosec	Zeta	

Rx PA Appeals

Inpatient Days	158,772	181,603	4.0%
ER visits	166,903	164,943	1.2%
Physician Visits	910,413	876,982	3.9%
Physicians w/25+ Patients	4,337	4,289	1.1%
Physicians w/50+ Patients	3,258	3,184	2.3%
Specialist Visits	6,401	4,203	3.2%

SCR 54 TRACKING

SFY 2004 - Quarter 3 (July - September 2003)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles Recipients	905,644 841,221	860,591 712,846	4.1% 18.0%
Total Scripts Paid	3,544,437	3,263,385	8.0%
Total Scripts Paid with PA	141,980	110,295	
Rx PA Requests Denied	28	29	
Medications			
Accubal	Combipatch	Kemodrin	Pitressin
Accutell	Copaxone	Kytril	Protonix
Accutetic	Careg	Lornist	Pratropin
Aceon	Caver-HS	Lorntus	Provigil
Aciphex	Cazar	Levoquin	Prazac Weekly
Actiq	Dantrolle	Levitol	Pulmicort
Activella	Darvon-N	Lexapro	Pulmicort Turbuhaler
Acular	Desoxyn	Mitior	QVAR
Aerobid	Dextrol	Loprax	Rabif
Aerobid-M	Dextro LA	Lorabid	Rameron
Alduron	Diazomel	Lovenox	Remeron SOL TAB
Allegra	Doral	Lumigan	Rescule
Allegra-D	Duoneb	Mazair Autohaler	Restori
Anace	Dynacirc	Mazdone	Restori 7.5MG
Alupent	Dynacirc CR	Mentax	Rhinocort
Ametek	Efexor XR	Methergip	Rhinocort Aqua
Amceton	Evista	Mycelax	Rowosa
Anzemet	Famvir	Nasocort	Roxicodone
Aquachloral	Femist	Nasocort AQ	Sordien
Arthrotec 50	Flonase	Nasorel	Scopace
Arthrotec 75	Flarin	Neuderm	Serzone
Aselin	Forteo	Nizatidine	Soma
Atacand	Foxal	Noroxin	Sonata
Atacand HCl	Genotropin	Norvosc	Spectazole
Atavancil	Glucophage XR	Opium	Sporanox
Avadine	Glucovance	Oxbiot	Statilene
Avapro	Glyset	Oxycontin	Synolips DC
Avid	Humalog	PCP	Teveten
Becanace AQ	Humalog Mix 75/25	Pentac	Teveten HCT
Benict	Humotropel	Pentasa	Tizac
Betalopace AF	Humulin 50/50	Percocet 10-325MG	Torecon
Centose	Humulin 70/30	Percocet 2.5-325MG	Vocyte
Codein w/Codeine	Humulin L	Percocet 7.5-325MG	Vancendose AQ
Cordene SR	Humulin N	Pepcid	Vontris
Cedax	Humulin R	Prandin	Vosca
Celebrex	Humulin U	Provachol	Verelan PM
Cefalex	Hyzac	Piapro	ViEND
Cefaclor	Inderal LA	Prevacid	Viox
Cefotaz	Kadian	Prevpac	Volmax
Rx PA Appends			
Inpatient Days	211,780	173,080	22.4%
ER Visits	140,013	138,071	7.9%
Physician Visits	912,298	828,154	10.2%
Physicians w/25+ Patients	4,634	4,283	8.2%
Physicians w/50+ Patients	3,498	3,155	10.9%
Specialist Visits	6,487	6,266	3.7%

Total Drugs: 164

SCR 54 TRACKING

SFY 2003 - Quarter 3 (October - December 2003)

Information Collected	Current Quarter	Previous Year Quarter	Percent Change	
Eligible Recipients	918,670	881,017	+4.3%	
Total Scripts Paid	3,670,640	3,776,546	-2.6%	
Total Scripts Paid with PA	147,027	141,080		
In PA Requests Denied	45	26		
Medications	3	0		
Acutane	Capoten	Kytril	Pillasec	Zantac Effervesce
Accupril	Coreg	Loratad	Provigil	Zelio
Acturetic	Covera-HS	Loratad	Prozac Weekly	Zomig
Acon	Cosoril	Levoflox	Pulmicort	Zomig ZMF
Aciphex	Dantrium	Tenex	Pulmicort Turbuhaler	Zydene
Actiq	Darvon-N	Upfer	Rabill	Zyrtec
Activitekt	Desoxyn	Lopraz	Relevra	Zyrtec Syrup
Acutax	Dextrol	Toradol	Relpax	Zyrtec-D
Acutax LS	Dextro LA	Lovenox	Remeron 50,1AB	
Acutax FF	Diflunest	Lumigan	Rescula	Total Drugs: 160
Adderall	Doral	Mazekit Autohalter	Restrin 7.5MG	
Akineton	Duoneb	Mavlan	Rhinocort	
Allegro	Dynacirc	Mentax	Rhinocort Aqua	
Allegro-D	Dynacirc CR	Metoglip	Rowasa	
Altace	Econazole Nitrate	Mycellex	Roxicodone	
Alpracet	Effexor XR	Nasacort	Saxatam	
Amerge	Evista	Nasacort AQ	Serevent	
Anzemet	Famvir	Nasorel	Senzar	
Arthrotec 50	Femhir	Nefazodone HCl.	Sonata	
Arthrotec 75	Flodin	Nextum	Spectizole	
Atelmin	Foradil	Nimotop	Sporanox	
Alzacard	Forteo	Nizatidine	Sputifer	
Alzacard HCl	Frova	Noroxin	Synalges-DC	
Allromam	Genotroph	Novasc	Tasmar	
Arid	Glucophage XR	Offloracain	Teveten	
Beclovent	Humalog	Oplum	Teveten HC1	
Becozene AQ	Humalog Mix 75/25	Oxitrol	Ticlid	
Betapace AF	Humatope	Oxycontin	Triclopidine HCL	
Capitol w/Codeine	Humulin 50/50	PCE	Volvyle	
Cardene SR	Humulin 70/30	Perflox	Voncanese AQ	
Cedar	Humulin I	Perflox	Vonceril	
Cetril	Humulin N	Perflox	Vanith	
Celebrex	Humulin R	Percocet 10-325MG	Vanitol HFA	
Cetexa	Humulin U	Percocet 25-325MG	Vanitol PM	
Climax	Inderal LA	Percocet 7.5-325MG	VFEND	
Colazol	Ipratropium Bromide	Pletal	Volmax	
Comiptouch	Kadion	Provachol	Vospire ER	
		Prevpac	Welchol	
Rx PA Appeals				
Inpatient Days	188,473	191,270	-1.5%	
ER Visits	146,826	161,352	-9.0%	
Physician Visits	961,707	987,080	-2.6%	
Physicians w/25+ Patients	4,419	4,375	1.0%	
Physicians w/50+ Patients	3,331	3,273	1.6%	
Specialist Visits	6,449	6,405	0.7%	

SCR 54 TRACKING

SFY 2003 - Quarter 3 (January - March 2004)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Enquiries Recipients	941,049	895,090	5.2%
Total Scripts Paled	919,112	760,295	20.9%
Total Scripts Paled with PA	3,756,741	3,463,921	7.9%
Total Scripts Paled with PA	162,032	96,159	56.1%
Rx PA Requests Denied	23	0	

Medications

Accupill	Cetor	Lantus	Pulmicort Respules	Zomig ZMT
Accutec	Dantrol	Levotol	Pulmicort Turbulader	Zydone
Acten	Darvan-N	Lipitor	Robit	Zytec
Actithex	Desoxyn	Lopax	Relpox	Zytec Syrup
Aclta	Detrol	Lorabid	Remon L.S.I.A.B	Zytec-D
Activella	Detrol LA	Lovenox	Rescata	
Aculor	Dikronet	Lumigan	Restoril 7.5MG	Total Drugs: 168
Aculor LS	Doral	Mazola Autohaler	Rhinocort	
Aculor PF	Duanub	Mazoline	Rhinocort Aqua	
Akineton	Dynactic	Mentax	Roxosed	
Alloptia	Dynactic CR	Melotilp	Portacodone	
Allegra-D	Econazole Nitrate	Mobic	Soratam	
Allace	Effexor XP	Mycetex	Serevent	
Alporen	Ermodine	Mycostatin Pastilles	Serzone	
Amersys	Evista	Nasocort	Sonata	
Anarmel	Famuk	Nasocort AQ	Spectazole	
Aquachloral	Femhist	Nasarel	Sparanox	
Arthrotec 50	Flavin	Naxun	Strattera	
Arthrotec 75	Foradil	Nimotop	Synalgos-DC	
Aselin	Forteo	Nitrofildina	Tasmar	
Atracand	Frova	Noxoth	Teveten	
Atracand HCl	Genotropin	Novasc	Teveten HCl	
Atravent	Glucephegabe XR	Oftloxacin	Ticlid	
Avid	Humalog	Opium	Ticlopidine HCl	
Bedolaveni	Humalog M/L 75/25	Oxitol	Volcycle	
Becorase AQ	Humalogre	Oxycontin	Vancance AQ	
Bulapace AF	Humulin 50/50	Oxyfrat	Vonifin	
Conas	Humulin 70/30	PCE	Ventolin HFA	
Cordene SR	Humulin L	Penlac	Verelan PM	
Cedex	Humulin N	Perfaso	VFEND	
Cefzil	Humulin R	Percocet 10-325MG	Volmax	
Celebrex	Humulin U	Percocet 2.5-325MG	Vaspire ER	
Celoxa	Hyzoor	Percocet 7.5-325MG	Welchol	
Climara	Inderal LA	Pletal	Zantac Effervesce	
Colcar	Iproterol Bromide	Prevachol	Zette	
Combipatch	Kardon	Prevpac	Zomig	
Copaxone	Kytril	Provigil	Zomig Nasal	
Coveris-HS	Lornil	Prozac Weekly	Zomig Spray	

Rx PA Appeals	0	0	
Inpatient Days	208,503	189,477	10.0%
ER visits	149,176	172,380	-13.5%
Physician Visits	1,012,691	902,210	12.2%
Physicians w/25+ Patients	4,500	4,224	6.5%
Physicians w/50+ Patients	3,413	3,135	8.0%
Specialist Visits	6,404	6,381	0.4%

SCR 54 TRACKING

SFY 2004 - Quarter 4 (April - June 2004)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	943,097	907,804	4.0%
	930,935	803,681	15.6%
Total Scripts Pd	3,589,106	3,360,336	6.8%
Total Scripts Pd w/ PA	134,518	110,294	12.8%
Rx PA Requests Denied	26	0	

Medications

Accupril	Coozar	Lantus	Pulmicort Respules	Zomig ZMT
Accutane	Dantrolene	Levoflox	Pulmicort Turbuhaler	Zydone
Acon	Darvon-N	Uptite	Rebif	Zytec
Aciphex	Desoxyn	Lopax	Relpar	Zytec Syrup
Actiq	Detroit	Loratad	Pentagon SOL TAB	Zytec-D
Activite	Detroit LA	Lovenox	Rescue	
Acular	Didronel	Lumigan	Resori 7.5MG	
Acular LS	Doral	Mazek Autohaler	Rhinocort	
Acular PF	Duoneb	Mazdone	Rhinocort Aqua	
Aldosteron	Dynactic	Memox	Rowasa	
Allegra	Dynactic CR	Metoglip	Roxicodone	
Allegra-D	Econazole Nitrate	Mobic	Sorafen	
Allace	Effexor XR	Mycetex	Serevent	
Alupent	Emendine	Mycostatin Pastilles	Serzone	
Amerge	Evtis	Nasacort	Sonata	
Ansermet	Famvir	Nasacort AQ	Specleotide	
Aquachloral	Femhrt	Natrel	Spatanox	
Arthrotec 50	Flaxin	Neplim	Strattera	
Arthrotec 75	Foradil	Minotrop	Synagop-DC	
Atafin	Forfeo	Nizatidine	Tasmor	
Atacand	Frova	Noroxin	Teveten	
Aticard HCT	Ganatriptan	Norvoc	Teveten HCT	
Atrovant	Glucophage XR	Ofoxacin	Ticlid	
Azid	Humalog	Opium	Ticlopidine HCl	
Beclovent	Humalog Mix 76/25	Oxitrat	Valecyte	
Becorase AQ	Humalog	Oxycontin	Vancendox AQ	
Betapace AF	Humulin 50/50	Ozytrol	Vantin	
Conas	Humulin 70/30	PCT	Ventolin HFA	
Cordene SR	Humulin L	Pantac	Verelan PM	
Cedox	Humulin N	Pentosa	ViEND	
Cetil	Humulin R	Percocet 10-325MG	Volmax	
Celebrex	Humulin U	Percocet 2.5-325MG	Vospire ER	
Celecox	Hyzclar	Percocet 7.5-325MG	Welchol	
Chlora	Inderal LA	Pletol	Zantac Extended	
Colorad	Ipratropium Bromide	Provachol	Zetia	
Combibirth	Kodion	Previpac	Zomig	
Copaxone	Kytril	Provigil	Zomig Nasal	
Covera-HS	Lamill	Propac Weekly	Zomig Spray	

Rx PA Appeals	0	0	
Inpatient Days	207,943	186,772	10.2%
ER Visits	147,882	166,104	-11.4%
Physician Visits	1,012,691	902,210	12.2%
Physicians w/25+ Patients	4,526	4,337	4.3%
Physicians w/50+ Patients	3,475	3,258	6.7%
Specialist Visits	6,453	6,401	0.8%

SCR 54 TRACKING

SFY 2005 - Quarter 1 (July - September 2005)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	962,348	920,195	3.6%
Recipients	938,980	841,221	11.6%
Total Scripts Paid	3,659,239	3,544,437	0.4%
Total Scripts Paid with PA	118,897	141,943	-16.2%
Rx PA Requests Denied	23	0	

Medications

Acyclovir	Detroit	Mycelox	Vascor
Accutane	Detroit LA	Nasacort AQ	Verinair HFA
Acton	Diclofenac	Nasarel	Verelan PM
Aciphex	Doral	Nexium	VFEND
Actiq	Duoneb	Nimotop	Vospire ER
Activella	Dynoject CR	Nitroldine	Welchol
Aldomet	Dynoject CR	Noroxin	Zodilax
Allergo	Epogen	Novacec	Zantac Effervesce
Allergra-D	Evtista	Oftasoch	Zefia
Aloril	Femvir	Opium	Zomig
Alomide	Flutin	Oxycontin	Zomig Spray
Altace	Foradil	Oxytrol	Zomig ZMT
Aludent	Foraleo	PCE	Zymar
Amerge	Frova	Pentac	Zyrtec
Anzemet	Glucophage XR	Provigil PAC	Zyrtec Chew tabs
Arthrotec 50	Helioc	Previpac	Zyrtec Syrup
Arthrotec 75	Humalog	Provigil	Zyrtec-D
Atacand	Humalog Mix 75/25	Prozac Weekly	Total Drugs: 131
Atacand HCT	Humatrop	Pulmicort Respules	
Asta	Humulin 50/50	Pulmicort Turbuhaler	
Becanase AQ	Humulin 70/30	Rebil	
Cedax	Humulin L	Repxax	
Coriz	Humulin N	Remeiron SOL TAB	
Celebrek	Humulin R	Romicade	
Cetava	Humulin U	Rescula	
Cipro HC	Hyzaar	Rhinocort Aqua	
Climara	Inderal LA	Rowasa	
Clotrimazole	Kinect	Satin	
Cogner	Kytril	Sorafen	
Combipatch	Lambil	Serevent	
Comprona	Levator	Serostim	
Cortisoptin-HC	Lofibra	Sonata	
Covera-HS	Toprax	Sporanonix	
Cuzat	Toradol	Strattera	
Cystos	Lovenox	Teveten	
Dantrolen	Maxair Autohaler	Tevatan HCl	
Darvon-N	Metaglip	Ticlid	
Desoxyn	Mirtazapine Sol Tab	Vantin	

Rx PA Appeals	0	0	
Inpatient Days	206,951	211,780	-2.3%
ER visits	140,606	149,013	-5.6%
Physician Visits	922,831	911,605	1.2%
Physicians w/25+ Patients	4,608	4,639	-0.7%
Physicians w/50+ Patients	3,486	3,498	-0.3%
Specialist Visits	6,538	6,487	0.8%

SCR 54 TRACKING

SFY 2005 - Quarter 4 (October - December 2004)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	972,519	937,253	3.6%
Recipients	958,021	884,523	8.3%
Total Scripts Paid	3,892,013	3,679,649	5.8%
Total Scripts Paid with PA	98,639	146,799	-32.8%
Re: PA Requests Denied	0	0	

Medications

Accutin	Epoegen	Provigil PAC	
Acliplas	Evista	Precose	Total Drugs: 114
Actiq	Famihrt	Prostatix	
Activabeta	Foradil	Provigil	
Alkaphton	Forteo	Prozac Weekly	
Allergia	Novo	Pulmicort Turbhaler	
Allergro-D	Heldiac	Relsid	
Aloril	Humalog	Ripax	
Alomide	Humalog Mix 75/25	Rimicade	
Alupent	Humantropine	Rhinocort Aqua	
Ammerge	Humulin 50/50	Rowasa	
Arvenet	Humulin 70/30	Sarafem	
Arthrotec 50	Humulin L	Serevent	
Arthrotec 75	Humulin N	Saxatilim	
Atacand	Humulin R	Sonata	
Atrocard HC1	Humulin U	Sporanoz	
Axert	Inderal LA	Strattera	
Axit	Kemadrin	Synoligos-DC	
Becconate AQ	Kineret	Tasmar	
Cardene SR	Kytril	Ticlid	
Cedax	Lantus	Ticloplastine HCl	
Cefalex	Lefibra	Ventolin HFA	
Ciclosporax	Lopraz	Verevan PM	
Cipa HC	Lorabid	VFEND	
Citalopram HBR	Lovenox	Vospira ER	
Citmano	Mazair Autohaler	Welchol	
Clotrimazole	Mesalamine	Zaditor	
Combipatch	Myceteze	Zantac Effervesce	
Capurane	Nasacort AQ	Zetia	
Cortisportin-TC	Nasarel	Zomig	
Coveras-HS	Nasonez	Zomig Spray	
Credor	Nimotop	Zomig ZM	
Dantium	Nicardpine	Zymox	
Darvan-N	Noxodin	Zytec	
Detrol	Oxycontin	Zytec Chew Tabs	
Detrol LA	Pantoprine	Zytec Syrup	
Dikronel	Pantac	Zytec-D	
Duoneb	Prandin		

Re: PA Appeals	0	0	
Inpatient Days	208,441	188,473	10.6%
ER visits	146,431	140,826	-3.3%
Physician Visits	1,033,315	901,701	7.4%
Physicians w/25+ Patients	4,712	4,419	6.6%
Physicians w/50+ Patients	3,585	3,331	7.6%
Specialist Visits	6,584	6,449	1.6%

SCR 54 TRACKING

SFY 2005 - Quarter 3 (January - March 2005)

Information Collected	Current Number	Previous Year Quarter	Percent Change
Eligible Recipients	982,544	950,709	3.3%
Total Script's Pd	971,355	919,112	5.7%
Total Scripts Pd with PA	4,102,040	3,758,741	9.1%
Total Scripts Pd with PA	82,449	152,032	-45.8%
Rx PA Requests Denied	10	0	
Medications			
Accutane	Eviata	Provigil	
Acthar	Femhrt	Prazac Weekly	Total Drugs: 119
Actiq	Foradil	Pulmicort Respules	
Activelle	Fontec	Pulmicort Turbohaler	
Athetox	Frova	Quinapril	
Allegro	Heptac	Quinapril HCl	
Allegro-D	Humalog	Rebil	
Allegro-D 12 Hour	Humalog Mix 75/25	Relpax	
Allegro-D 24 Hour	Humatropes	Remicade	
Alzacil	Humulin E/50	Rhinocort Aqua	
Atomide	Humulin 70/30	Rowasa	
Atropent	Humulin I	Solefen	
Amprage	Humulin N	Sotaflox	
Anzemet	Humulin R	Suvorenil	
Arthrotec 50	Humulin U	Sonata	
Arthrotec 75	Inderal LA	Spoxone	
Atosend	Itraconazole	Strattera	
Atosend HCl	Kytril	Synaptog+DC	
Aver	Lamisil	Tacid	
Avid	Levator	Ticlopidine HCl	
Bectoncase AQ	Lessel	Vancenase AQ	
Cardene SR	Loflyra	Vençen	
Cedax	Lopax	Ventolin HFA	
Celera	Loratad	Verelan PM	
Ciclopirox	Lovenox	VFEND	
Cipro HC	Moxifl Autohaler	Vospire ER	
Climara	Mycelias	Witchhol	
Clotrimazole	Nasacort AQ	Zodstar	
Combipatch	Nasarel	Zantac Effedose	
Copaxone	Nasonex	Zetka	
Cortisplain-IC	Nizatidine	Zomig	
Covera-HS	Noroxin	Zomig Spray	
Clexor	Oxycodone HCl	Zomig ZM	
Dantrolum	Oxycontin	Zymar	
Dantrolene Sodium	Oxytrol	Zytec	
Darvan-N	Pantac	Zytec Chew Tabs	
Detrol	Prandin	Zytec Syrup	
Detrol LA	Provigard PAC	Zytec-D	
Dronnel	Prascoc		
Duaneo	Previpac		
Épogen	Protonix		
Rx PA Appeals	0	0	
Inpatient Days			
ER visits	215,150	208,503	3.2%
	170,903	149,176	14.6%
Physician Visits	1,097,856	1,012,691	8.4%
Physicians w/25+ Patients	4,724	4,500	5.0%
Physicians w/50+ Patients	3,634	3,413	6.5%
Specialist Visits	6,582	6,404	2.8%

SCR 54 TRACKING

SFY 2005 - Quarter 4 (April - June 2005)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	969,890	962,873	2.8%
	983,512	931,935	5.6%
Total Scripts Paid	3,846,607	3,869,106	7.2%
Total Scripts Paid with PA	78,591	134,518	-41.0%
Rx PA Requests Denied	0	0	

Medications

Accupril	Epoegen	Provigil PAC	
Acliphex	Eristo	Precote	Total Drugs: 114
Actiq	Femhrt	Protonix	
Activella	Foradil	Provigil	
Albuterol	Forsteo	Prozac Weekly	
Allergra	Frava	Pulmicort Turbohaler	
Allergro-D	Heldiac	Rebil	
Alloccil	Humalog	Relpax	
Alomitrile	Humalog Mix 75/25	Rimicade	
Alupent	Humatope	Rhinocort Aqua	
Amerige	Humulin 50/50	Rowasa	
Anzemet	Humulin 70/30	Sorafen	
Arthrotec 50	Humulin L	Serevent	
Arthrotec 75	Humulin N	Seroxatin	
Atacand	Humulin R	Sonata	
Atacand HCl	Humulin U	Sporanox	
Averil	Inderal LA	Stolafex	
Avid	Kemadrin	Synagis-DC	
Beconase AQ	Kinect	Tasmar	
Cardene SR	Kytril	Ticlid	
Cedex	Lamisil	Ticlopidine HCl	
Celox	Lofibra	Venlafax HFA	
Diclopirax	Lopirox	Verelan PM	
Cloia HC	Lorabid	VFEND	
Clozapine HBR	Lovenox	Vospire ER	
Climara	Motrin Autohaler	Welchol	
Clotrimazole	Mesalamine	Zodilor	
Combipatch	Mycelex	Zomig Effudose	
Copaxone	Nasacort AQ	Zetia	
Contropain-TC	Nasarel	Zomig	
Covera-HS	Nasonex	Zomig Spray	
Crestor	Nimotop	Zomig ZMT	
Dorium	Nizatidine	Zymar	
Darvon-N	Noradin	Zytec	
Detrol	Oxycontin	Zytec Chew Tabs	
Detrol LA	Pantopline	Zytec Syrup	
Didronel	Penlac	Zyrtec-D	
Duoneb	Prondin		

Rx PA Appeals	0	0	
Inpatient Days	224,101	207,946	7.8%
ER visits	169,396	147,982	14.5%
Physician Visits	1,021,581	968,985	5.4%
Physicians w/25+ Patients	4,922	4,525	8.8%
Physicians w/50+ Patients	3,009	3,475	9.6%
Specialist Visits	6,657	6,463	3.2%

SCR 54 TRACKING

SFY 2006 - Quarter 1 (July - September 2005)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	1,002,110	981,285	2.1%
Recipients	982,187	939,987	4.5%
Total Scripts Pd	3,521,320	3,559,239	-1.1%
Total Scripts Pd with PA	109,782	118,897	-7.7%
Rv PA Requests Denied	10	0	
Medications			
Accupril	Clofibrate	Uptite	Rhinocort Aqua
Aciphex	Coreg	Loribra	Saletra
Actiq	Cortiziparin-TC	Lopidox	Sonctura
Alderton	Covera-HS	Lorabid	Sorafen
Allergia	Cymbalta	Mazoli Autohaler	Serevent
Allergo-D 12 Hour	Dantrolum	Mycelex	Sercalim
Allergo-D 24 Hour	Dantrolene Sodium	Nasacort AQ	Spirancor
Albutil	Darvon-N	Nasorel	Strattera
Alomide	Dextrof	Nasonex	Telavert
Alupent	Dextrof LA	Nexium	Telavert HCl
Amerge	Diltiazel	Nitazadine	Ticlid
Antara	Dipentum	Noroxin	Ticlopidine HCl
Anzemet	Duoneb	Novace	Vanceril
Arthrotec 50	Dynactic	Nutropin	Ventolin HFA
Arthrotec 75	Ezogen	Omeprazole	Vesicare
Asacol	Eviato	Opium	ViSEND
Atacand	Hanacate	Oxycodone HCl	Vaspire ER
Atacand HCl	Fosatril	Oxycodinit	Welchol
Avolide	Forinol	Potofadone	Wellbutrin XL
Avondox	Furo	Ponstol DC	Zoloft
Avopca	Genotropin	Ponstol SS	Zomig Efferdose
Avinza	Hebdac	Perloc	Zegretik
Avodart	Humalog	Prandin	Zella
Axa	Humalog Mix 75/25	Provachol	Zymor
Becotide AQ	Humatrop	Provigard PAC	Zytec
Benicar	Humulin 50/50	Precose	Zytec Chew tabs
Benicar HCl	Humulin 70/30	Pteripac	Zytec Syrup
Caduet	Humulin L	Pilosec	Zytec-O
Canoso	Humulin N	Protonix	
Cedax	Humulin R	Provigil	Total Drugs: 142
Celexa	Humulin U	Provoc Weekly	
Cloloplex	Imfiteax	Pulmicort Respules	
Cipro HC	Imfiteax Spray	Pulmicort Turbuhaler	
Claritin	Imfiteax Tablet	Rhinapell	
Claritin Tab Rapid	Itaconizazole	Quibitin HCl	
Claritin Tablet	Knexel	Relpax	
Climaro	Kyrill	Remicade	
Climaro Pro	Lornist	Renagel	
Rv PA Appeals	0	0	
Inpatient Days	205,247	204,951	-0.8%
ER visits	146,485	140,606	4.2%
Physician Visits	891,097	922,631	-3.4%
Physicians w/25+ Patients	4,667	4,608	1.3%
Physicians w/50+ Patients	3,542	3,466	1.6%
Specialist Visits	6,673	6,538	2.1%

SCR 54 TRACKING

SEY 2006 - Quarter 2 (October - December 2005)

Information Category	Current Quarters	Previous Year Quarters	Percent Change
Eligibles	1,017,366	988,026	3.0%
Recipients	953,493	958,021	-0.2%
Total Scripts Pd	3,691,806	3,692,013	-0.1%
Total Scripts Pd with PA	153,053	98,639	55.8%
Rx PA Requests Denied	20	0	
Medications			
Abilify	Clopipex	Geodon	Norvasc
Accutane	Clozar	Grilulvin V	Omeprazole
Acon	Clozan Ointment	Heidoc	Optivar
Aciphex	Closo	Humalog	Oxitrol
Actiq	Cipro HC	Humalog Mix 75/25	Oxycodone HCl
Altretan	Cipro Suspension	Humatropin	Oxycontin
Alomast	Cipro XR	Humulin 50/50	Pantol DC
Allergo	Clofazex	Humulin 70/30	Pantol SS
Allergo-D 12 Hour	Cloflex Tab	Humulin L	Paracopax
Allergo-D 24 Hour	Claritin Tab Rapid	Humulin N	Pregesys
Alotris	Climara	Humulin R	Pentoline
Alamide	Climara Pro	Humulin U	Perloc
Alupent	Clofazazole	Imitrex Tablet	Ponset
Amerge	Combunox	Iralol	Prandin
Antrala	Copegus	Kemadrin	Provachol
Anzemet	Coseq	Ketek	Precose
Arthrotec 50	Corespiron-IC	Ketek Pak	Prevacid Naprapac
Arthrotec 75	Coverid-HS	Kytril	Prevpac
Asocul	Cytel	Levagrin	Priosec
Atetlin	Cymbalta	Levatal	Protonix
Azercand	Dantrolm	Liptor	Provigil
Azocand HCl	Dantrolene Sodium	Lofibra	Prazac Weekly
Avadate	Desmoxyn	Loprox	Pulmicort Respules
Avandamol	Dextrof	Lorabid	Pulmicort Turbuhaler
Avandia	Dextrof LA	Lunesta	Quibin
Avaprio	Doral	Mavik Autovenol	Relax
Aviziru	Duoden	Mentax	Remicade
Avodart	Dymatic	Metoglip	Renogal
Axic	Epopogen	Mobic	Rhinocort Aquia
Baclofen AQ	Etracet	Mycetex	Ribasphere
Bentilar	Eviita	Natlin	Ribovin
Bentilar HCl	FaciTive	Norocan AQ	Sandura
Boniva	Fontanyl	Nasorel	Sarelem
Caduel	Fexofenadine HCl	Nasonex	Scopace
Comato	Foradil	Nelum	Serevent
Cedar	Forleo	Nimotop	Serastim
Celabrew	Frova	Nizolidine	Sparanox
Celoxa	Genotrophin	Noradrin	Skatera
Rx PA Appeals	0	0	Total Drugs: 179
Inpatient Days	202,170	208,441	-3.0%
ER visits	158,505	146,431	8.2%
Physician Visits	846,863	1,033,315	-18.0%
Physicians w/25+ Patients	4,261	4,712	-9.5%
Physicians w/50+ Patients	3,229	3,565	-9.9%
Specialist Visits	7,633	6,554	14.9%

SCR 54 TRACKING

SPY 2006 - Quarter 3 (January - March 2006)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Flagship Recipients	1,020,597	996,438	+2.4%	
Total Scripts Pdls	949,056	971,355	-2.2%	
Total Scripts Pdls with PA	2,349,430	4,102,040	-37.8%	
Total Rx PA Requests Denied	114,203	82,449	38.5%	
Rx PA Requests Denied	2)	0		
Medications				
Abilify	Clozaril Ointment	Humalog	Ponstel DC	VFEND
Accutane	Cipro	Humulin 50/50	Ponstel SS	Vigamox
Acon	Cipro HC	Humulin 70/30	Percozo	Vospire ER
Aciphex	Cipro Suspension	Humatropo	Pegasys	Welchol
Actta	Cipro XR	Humulin 70/30	Pernolite	Wellbutrin
Astelin	Claritin tab	Humulin L	Penloc	Wellbutrin XL
Akzentri	Claritin Tab.Rapids	Humulin N	Pontel	Xolotan
Allegra	Climara	Humulin R	Prandin	Zaditor
Allegra-D 12 Hour	Climara Pro	Humulin U	Provachol	Zomig Effervesce
Allegra-D 24 Hour	Combunox	Imitrex Spray	Prevacid Napropac	Zegret
Alzact	Copegus	Imitrex Tablet	Pritacec	Zefla
Almetria	Coreg	Inflagen	Protonix	Zyprexa
Alupent	Contiparin-TC	Istalol	Provigil	Zyprexa Zydis
AmERGE	Cytora	Ketek	Prozac Weekly	Zytriac
Antara	Cymbalta	Ketes Pak	Pulmicort Respules	Zytriac Chew Tabs
Antiemet	Dantrolene	Kytril	Pulmicort Turbuhaler	Zytriac Syrup
Antro	Dantrolene Sodium	Levaquin	Rukin	Zytriac-D
Arthrotec 50	Darvon-N	Levatoral	Repath	
Arthrotec 75	Desoxyn	Liptor	Rimicade	Total Drugs: 148
Asacol	Dextro	Lofibra	Renagel	
Aspirin	Dextro LA	Lorabid	Rhinocort Aqua	
Ateplase	Dilectol	Lunesta	Ribusphere	
Atacand	Dipentum	Metax	Ribavirin	
Atacand HCT	Duoneb	Melotrop	Saletra	
Avodart	Dynactic	Mobic	Sancuturo	
Avandamet	Epicor	Motrin	Sorafen	
Avandia	Erlacoz	Nasorel	Strattera	
Avapro	Favist	Neutum	Symbrys	
Avizor	Factive	Nimotop	Syringos-DC	
Avodart	Fensonyl	Nizatidine	Tasmor	
Avodart	Fesoterodine HCL	Noroxin	Tequin	
Bentilar	Foradil	Norvasc	Tevelen	
Bentilar HCT	Forera	Nutrapin	Tevafer (HC)	
Boniva	Frava	Omeprazole	Ticida	
Caduce	Genotropin	Opdiva	Ticlopidine HCL	
Centoxo	Geodon	Oxitrol	Vancendose AQ	
Cettebrex	Glibizide-Metformin	Oxycodeone HCL	Vanceril	
Ciloxan	Griturin V	Oxycontin	Vesticare	
Rx PA Appeals	0	0		
Inpatient Days	219,998	216,156	+2.3%	
ER visits	160,409	170,900	-6.1%	
Physician Visits	931,132	1,097,856	-15.2%	
Physicians w/25+ Patients	4,460	4,724	-6.6%	
Physicians w/50+ Patients	3,358	3,634	-7.6%	
Specialist Visits	8,350	6,582	26.9%	

SCR 54 TRACKING

SPY 2006 - Quarter 4 (April - June 2006)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligible Recipients	1,015,488	1,002,696	+1%	
	973,906	983,512	-1.0%	
Total Scripts Paid	2,337,055	3,846,607	-39.2%	
Total Scripts Paid with PA	96,199	78,591	22.4%	
Rx PA Requests Denied	13	0		
Medications				
Abilify	Cloza XR	Humalog Mix 75/25	Pillosec	Zytec
Accutane	Claritin	Humatrop	Proscar	Zytec Chew tabs
Aceon	Claritin RediTabs	Humulin 70/30	Protonix	Zytec Syrup
Aciphex	Claritin Syrup	Humulin L	Provigil	Zytec-D
Actiq	Claritin Tab	Humulin N	Prozac Weekly	
Akhetorin	Claritin-Tab Rapid	Humulin R	Pulmicort Respules	
Alomast	Claritin-D 12 Hour	Humulin U	Pulmicort Turbuhaler	
Allergio	Claritin-D 24 Hour	Infergen	Quixin	
Allergio-D 12 Hour	Climara Pro	Innoprin XL	Relpax	
Allergio-D 24 Hour	Clozal	Kereks	Rimicade	
Alloccil	Combunox	Ketek Pak	Renagel	
Almetript	Copaxone	Kytril	Rhinocort Aqua	
Alupent	Coricospin-TC	Levaquin	Risosphere	
Ambien CR	Covera-HS	Lipitor	Ritavirin	
Amerge	Cytel	Lorabid	Sarafem	
Antosian	Cymbalta	Magnesium 400 RX	Sonata	
Antro	Dantrium	Merits	Strattera	
Antezmel	Dextrol	Metaglip	Symbax	
Arthrotec 50	Dextro LA	Mobic	Tegquin	
Arthrotec 75	Diclofenac	Natrin	Teveten	
Atstein	Duoden	Nasorel	Tevenen HCl	
Atrocard	Dynaciac	Nimotop	Ticla	
Atrocard HCT	Epopen	Novace	Ticlopidine HCl	
Avadide	Ertaczo	Omacor	Triglide	
Avandia	Evista	omeprazole	VFEND	
Avanza	Factive	Optivar	Vigamox	
Avid	Fentanyl	Ostelin	Vospire ER	
Baclovent	Fexofenadine HCl	Oxyacetylene HCl	Welchol	
Becorase AQ	Fordatil	Oxycontin	Wellbutrin SR	
Boniva	Forteo	Pantol DC	Xalatan	
Budeprion SR	Fortical	Pantol SS	Zactar	
Bupropion HCl	Frova	Parcopa	Zantac Effedose	
Cardeut	Gendophin	Perflox	Zengard	
Cardene SR	Glibizide-Metformin	Ponstel	Zeria	
Cefobidex	Giltulvin V	Prandin	Zomig	
Clexan	Giseofulvin	Provachol	Zomig ZM	
Cipro HC	Humalog	Provastatin Sodium	Zyprexa	
Cipro Suspension	Humalog Mix 50/50	Prevacid Napropac	Zyprexa Zydis	
Rx PA Appeals	0	0		
Inpatient Days	219,320	224,101	-2.1%	
ER visits	167,364	169,396	-1.2%	
Physician Visits	930,777	1,021,561	-8.9%	
Physicians w/25+ Patients	4,541	4,722	-7.7%	
Physicians w/50+ Patients	3,515	3,809	-7.7%	
Specialist Visits	7,736	6,667	16.2%	

SCR 54 TRACKING

SIV 2007 - Quarter 3 (July - September 2006)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	999,303	1,021,111	-2.1%
	942,339	982,187	-4.1%
Total Scripts Paid	2,075,266	3,621,320	-43.1%
Total Scripts Paid with PA	77,683	109,782	-29.1%
Rx PAR Requests Denied	14	0	
Medications			
Abilify	Cimara Pro	ketek	Quixin
Accutane	Catalyz	Ketek Pot	Retepox
Acon	Combicas	Kefotifen Fumarate	Remicade
Aciphex	Copaxone	Kytril	Rhinocort Aqua
Actiq	Cartigrain-IC	Levoquin	Ribopak
Actionel with Calcium	Covera-HS	Uptite	Ribosphere
Altamise	Cumbalto	Lorabid	Ribovirin
Allergro	Darvon-N	Magnembed 400 Rx	Sarafem
Allergro - D 12 hour	Dextrol	Mentix	Sondal
Allergro - D 24 hour	Dextrol LA	Mesaglip	Strattera
Alzact	Didronel	Mobic	Symbax
Alomide	Duoneb	Natlin	Tequin
Alupent	Dynoctic	Nasarel	Tavatan
Ambien CR	Epopgen	Noroxin	Teveten HCl
Amerge	Ericato	Novasc	Ticlid
Antara	Favista	Nutropin	Ticlopidine HCl
Antemet	Foxicure	Omactar	Triglide
Arthrotec 20	Fentanyl	Omeprazole	ViEEND
Arthrotec 75	Fosafenoxadole HCl	Opiktar	Vigomax
Atelvia	Finstazide	Oxitrol	Vospire ER
Azacand	Foradil	Oxydone HCl	Wethchol
Azacand HCl	Forfas	Oxycontin	Wellbutrin SR
Avinzo	Fortifant	Pantol DC	Xolaton
Becorazole	Frova	Pantol SS	Zaditor
Boniva	Genotropin	Parcopa	Zegretid
Budenoside SR	Geodon	Penoxic	Zetta
Supraplon HCl	Glytazide-Metformin	Parstel	Zomig
Carduel	Glitulin V	Prandin	Zomig ZMT
Cellobex	Humalog	Provachol	Zyflo
Citavan	Humalog Mix 50/50	Pravastatin sodium	Zyprexa
Cipro HC	Humalog Mix 75/25	Prevacid Naprapac	Zyprexa Zyldz
Cipro Suspension	Humaloge	Priosec	Zytec
Cipro XR	Humulin 70/30	Proscar	Zytec Chew Tabs
Claritin RedTabs	Humulin N	Protonix	Zytec Syrup
Claritin Syrup	Humulin R	Provigil	Zytec-D
Claritin Tab	Inflagen	Prazac Weekly	
Claritin - D 12 Hour	Innoprin XL	Pulmicort Resules	
Claritin - D 24 Hour	Istadol	Pulmicort Turbuhaler	
			Total Drugs: 149
Dr PA Appeals	0	0	
Inpatient Days	198,568	205,247	-4.7%
ER visits	144,075	145,485	-1.6%
Physician Visits	777,642	891,097	-12.7%
Physicians w/25+ Patients	4,371	4,667	-6.3%
Physicians w/50+ Patients	3,326	3,542	-6.1%
Specialist Visits	7,661	6,673	14.8%

SCR 54 TRACKING

SFY 2007 - Quarter 2 (October - December 2006)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligibles Recipients	993,534 832,520	1,021,684 955,693	-3.5% -2.4%	
Total Scripts Paid	2,458,987	3,691,806	-33.4%	
Total Scripts Paid with PA	91,399	153,653	-40.6%	
Rx PA Requests Denied	0	0		
Medications				
Abilify	Cilmara Pro	Levotol	Prevacid Napropac	Xolatol
Ability Discreet	Colazal	Lipitor	Prilosec	Zocor
Accutab	Combunox	Lopressor	Proquin XR	Zegerid
Adaphes	Copaxone	Lopressor Shampoo	Prostar	Zefar
Actiq	Cortizporin-TC	Lorabid	Poloftix	Zetia
Actonal	Cymbalta	Magnesibind 400 Rx	Provigil	Zoloft
Allerga	Desoxyn	Mucofenamate Sodium	Pritac Weekly	Zomig
Allerga -D 12 Hour	Dextro	Melagrip	Pulmicort Respules	Zomig ZMT
Allerga -D 24 Hour	Dextro LA	Melatoperphenol Sulfate	Pulmicort Turbuhaler	Zylo
Alomide	Duoneb	Mobic	Quilit	Zyprexa
Alupent	Dynacirc	Nasorel	Ranitac	Zyprexa Zydis
Ambien CR	Epogen	Nimotop	Razadyne	Zytec
Amerite	Ertaczo	Novacec	Razadyne ER	Zytec Chew Tabs
Antara	Evista	Novolin 70/30	Relpar	Zytec Syrup
Arremet	Factive	Novolin N	Rimoclade	Zytec-D
Atidra	Fentanyl	Novolin N	Rhinocort Aquz	
Arthrotec 50	Fexofenadine HCl	Novolog	Ribosphere	Total Drugs: 167
Arthrotec 75	Fluasteride	Novolog Mix 70/30	Risovin	
Atacand	Fluticasone Propionate	Neuropin	Ritalin LA	
Atacand HCT	Foradil	Omocal	Sartamine HCl	
Avinza	Forteo	Omeprazole	Sonata	
Baclozone AQ	Fortical	Omnicef	Spectracet	
Budenoside SR	Frovap	Opadra	Sporanox	
Supraparin HCl	Fulvicin U/F Tablet	Opadra ER	Strattera	
Caduet	Genotropin	Opium	Symbax	
Cardene SR	Glipizide-Metformin	Optivar	Taveten	
Catelox	Glifluvin V	Orkelta	Teveten HCl	
Claxan	Glifluvin V Tablet	Ostrel	Ticlopidine HCl	
Claxan Ointment	Gliseutuvirin	Oxycodeone HCl	Triglide	
Cipro HC	Humalog Mix 50/50	Oxycontin	Ultram ER	
Cipro Suspension	Humalog	Pantol DC	Uniretic	
Cipro XR	Innoven XL	Pantol SS	Univasc	
Claritin RedTabs	Istalol	Percoce	Ventolin HFA	
Claritin RedPacks	Itraconazole	Perlac	Versed	
Claritin Syrup	Ketek	Ponstel	Vigamox	
Claritin Tab	Ketek Pak	Prandin	Vuslon	
Claritin -D 12 Hour	Kytril	Provachol	Welchol	
Claritin -D 24 Hour	Levoquin	Provastatin Sodium	Wellbutrin SR	
Rx PA Appeals	0	0		
Inpatient Days				
ER visits	215,219 152,848	202,170 158,505	-6.3% -3.0%	
Physician Visits	891,214	846,863	5.2%	
Physicians w/25+ Patients	4,405	4,261	3.4%	
Physicians w/50+ Patients	3,322	3,229	2.9%	
Spectraid Visits	7,299	7,533	-3.1%	

SCR 54 TRACKING

SFY 2007 - Quarter 3 (January - March 2007)

<u>Information Category</u>	<u>Current Quarter</u>	<u>Previous Year Quarter</u>	<u>Percent Change</u>
Eligibles Recipients	952,534 922,857	1,035,117 969,056	-8.0% -4.8%
Total Scripts Paid	2,583,046	2,549,430	1.3%
Total Scripts Paid with PA	93,715	114,203	-17.9%
No PA Requests Denied	7	0	
Medications			
Abilify	Climara Pro	Nasaler	Ritalin LA
Ability Discrell	Clozaril	Mimotop	Sertraline HCL
Accutab	Combutorix	Novasc	Sonata
Adaphes	Copaxone	Novolin 70/30	Spectace
Actiq	Contropain-TC	Novolin N	Spoonox
Actionex	Covera-HS	Novolin R	Srattera
Adderall XR	Cymbalta	Novolog	Symbax
Alavert	Darvon-N	Novolog Mix 70/30	Tevetan
Allegra	Detroit	Nutropin	Teveten HCT
Allegra Sup	Detroit LA	Ormacor	Ticlid
Allegra-D 12 Hour	Dotol	Omeprazole	Ticlopidine HCL
Allegra-D 24 Hour	Duaneb	Omnicef	Triglide
Alosaf	Dynacirc	Opanta	Ultram ER
Atorvastide	Epcogen	Opanta ER	Uniretic
Atupent	Enactra	Oplivor	Univasc
Ambien CR	Evista	Oxitrol	Ventolin HFA
Ancege	Factive	Oxycodone HCL	VFEND
Annavivite	Fentanyl	Oxycontin	Vigamor
Antara	Fesoferonide HCL	Panlor DC	Vospire ER
Anzemet	Fluasteride	Panlor SS	Vusion
Apidro	Fluticasone Propionate	Percoza	Welchol
Ativolt 30	Foradil	Percocet	Wellbutrin SR
Ativolt 75	Forlief	Ponstel	Xatolam
Alocand	Forlief	Prondin	Zaditor
Alocand HCl	Frova	Provachol	Zegrid
Avizato	Genofrapin	Provastatin Sodium	Zeflar
Bacanide AQ	Glibizide-Metformin	Prevacid Naproxec	Zetia
Buckleton SR	Glitidin V tablet	Prikaec	Zomig
Bupropion HCl	Humiceptape	Proquin XR	Zomig ZMT
Carfuel	Innapean XL	Proscol	Zybrexa
Cardene SR	Istrol	Protonix	Zybrexa Zydis
Celebrez	Itraconazole	Provigil	Zytec
Closon Ointment	Ketek	Prozac Weekly	Zytec Chew-Tabs
Clopo HC	Ketek Pak	Pulmicort Respules	Zytec Syrup
Clopo Suspension	Kytril	Pulmicort Turbuhaler	Zytec-O
Cipro XR	Lavacquin	Quixin	
Ciprofloxacin Suspension	Upnor	Ranidolor	Total Drugs: 165
Clarhex	Laprox Shampoo	Razodine	
Clarhex Repelets	Lorabid	Razodine ER	
Clarhex Syrup	Mectofenamate Sodium	Relpax	
Clarhex Tab	Metoglip	Remicade	
Clarhex-D 12 Hour	Mobic	Rhinocort Aqua	
Clarhex-D 24 Hour	Moexipril HCL	Ribavirin	
Rx PA Appeals	0	0	
Rx PA Medical Reviews	1		
Inpatient Days	229,892	219,996	4.5%
ER visits	167,021	160,409	4.1%
Physician Visits	907,670	931,132	-2.5%
Physicians w/25+ Patients	4,402	4,460	-1.3%
Physicians w/50+ Patients	3,376	3,356	0.6%
Specialist Visits	4,707	8,350	-19.7%

SCR 54 TRACKING

SFY 2007 - Quarter 4 (April - June 2007)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligibles	961,437	1,026,502	-6.5%
Recipients	939,536	973,305	-3.5%
Total Scripts Paid	2,420,379	2,337,056	3.6%
Total Scripts Paid with PA	95,649	96,199	-0.4%
Rx PA Requests Denied	5	0	

Medications

Abilify	Darvon-N	Norditropin	Sertraline HCL
Ability Disulfant	Dextro	Norditropin Norditrex	Sonata
Accutret	Dextro LA	Novolin 70/30	Spectrapor
Actiq	Dicloral	Novolin N	Sparanox
Actionel	Dipentum	Novolin R	Strattera
Almotriptal	Dilropan XL	Novolog	Symbax
Allergia	Doral	Novolog Mix 70/30	Taveten
Allergia -D 12 Hour	Duaneb	Novartil	Taveten HCT
Allergia -D 24 Hour	Epopen	Omecox	Ticlid
Aloclar	Eriocra	Ormeprazole	Ticlopidine HCL
Alomide	Estrazolam	Omnicef	Triglide
Alupent	Etidronate Disodium	Opano	Ultram ER
Ambien	Evieta	Opano ER	Unketic
Antara	Exubera Comb. Pack 12	Opitvar	Univasc
Arzneimel	Exubera Comb. Pack 15	Oseltam	Venlafax HFA
Apidrio	Exubera Kit	Oxycodone HCL	ViEND
Anthotect 60	Factive	Oxycontin	Vigamox
Anthotect 75	Fenofibrate	Pantol DC	Vospire ER
Atacand	Fenlonyt	Parcopa	Vuton
Atacand HCT	Fexofenadine HCL	Patanol	Welchol
Avined	Furozeptam HCL	Perloc	Wellbutrin XL
Averi	Futicasone Propionate	Persata	Xolotan
Azlect	Foradil	Ponstel	Zaditor
Bacanase AQ	Forstea	Prandin	Zegerid
Caudal	Fortical	Provachol	Zeliz
Cefdinir	Frowa	Provastatin Sodium	Zomig
Celebrex	Gifufitin V Tablet	Prevacid Naprapac	Zomig ZMT
Clozax Ointment	Humatapse	Prilosec	Zyprexa
Clopo HC	Invergen	Prquin XR	Zyprexa Zydis
Clopo Suspension	Innopran XL	Prosom	Zytec
Clopo XR	Istadol	Protonix	Zytec Chew Tabs
Clopi洛xacin ER	Itraconazole	Provigil	Zytec Syrup
Clopi洛xacin Suspension	Ketek	Prozoc Weekly	Zytec-D
Clarinet Releasable	Ketek Pak	Pulmicort	
Clarinet Total	Kytril	Pulmicort Respules	Total Drugs: 164
Clarinet -D 12 Hour	Levoquin	Pulmicort Turbuhaler	
Clarinet -D 24 Hour	Lopirox Shampoo	Gutin	
Combunox	Medolaminate Sodium	Raniklor	
Copegus	Metoprolol Tartrate	Razodine	
Coveris-HS	Mobic	Rephaox	
Cymbalta	Nasorel	Ramicodex	
Dolomite	Netazosdone HCL	Rhinocort Aqua	
	Nimotop	Rhinolin LA	

Rx PA Appeals	0	0	
Rx PA Medical Reviews	0	0	
Inpatient Days	220,652	219,320	0.7%
ER visits	156,503	167,364	-7.1%
Physician Visits	891,973	930,777	-4.2%
Physicians w/25+ Patients	4,761	4,541	4.8%
Physicians w/50+ Patients	3,745	3,515	6.5%
Specialist Visits	6,810	7,730	-12.0%

SCR 54 TRACKING

SFY 2008 - Quarter 1 (July - September 2007)

Information Collected	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	987,061	1,017,195	-3.0%
Eligible Recipients	920,734	942,339	-2.3%
Total Scripts Paid	2,104,857	2,075,286	5.3%
Total Scripts Paid with PA	77,932	77,883	0.1%
Rx PA Requests Denied	27	0	
Medications			
Abilify	Dipentum	Norditropin Norditrex	Sporanox
Ability Discreet	Ditropan XL	Novolin 70/30	Strattera
Accutab	Duoneb	Novolin N	Symbax
Aciphex	Emsam	Novolin R	Tasmar
Actiq	Epogen	Novolog	Taveten
Actonel	Entacra	Novolog Mix 70/30	Taveten HCl
Actonel with Calcium	Estazolam	Noxafri	Ticlid
Allergan	Etidronate Disodium	Nusoprin	Triglide
Allergo	Evtsta	Omecoxi	Ultura ER
Allergo-D 12 Hour	Exubera Comb Pack 12	Omeprazole	Unileptic
Allergo-D 24 Hour	Exubera Comb Pack 15	Omnicef	Univasc
Alocril	Exubera XR	Opana	Ventolin HFA
Alprazide	Frubera Pallett Pack	Opana ER	VFEND
Alupent	Focitive	Opdivor	Vigamox
Ambien	Fenofibrate	Oxisat	Vospire ER
Antara	Fentanyl	Oxycodone HCl	Vusion
Anremel	Feroferenadine HCl	Oxycontin	Wichol
Apidra	Fluoxetine HCl	Pantac DC	Wellbutrin XL
Atriplate 50	Fluvoxamine Propantheline	Penloc	Xolofan
Atriplate 75	Foradil	Pentasa	Xolegel
Atacand	Forsteo	Perstal	Zaditor
Atacand HCl	Fortical	Prandin	Zegretol
Avitrol	Frova	Provachol	Zella
Aver	Gelatin V Tablet	Pravastatin Sodium	Zomig
Baclofen AD	Humalog	Precacid Naprapac	Zomig ZMT
Caduet	Humatrop	Pilasec	Zyprexa
Celebrex	Infergen	Pilasec	Zyprexa Zydis
Clozapine	Innoven XL	Prosom	Zytec
Clozaril Ointment	Istatol	Protonix	Zytec Chew Tabs
Cipro HC	Itaconazole	Provigil	Zytec Syrup
Cipro Suspension	Ketek	Prozac Weekly	Zytec-O
Cipro XR	Kytril	Pulmicort Respules	
Clofibrate Relebabs	Levoquin	Pulmicort Turbuhaler	Total Drugs: 140
Clofibrate Tab	Lorilia	Quinit	
Clofibrate-D 12 Hour	Toprax Shampoo	Ranidol	
Claritin-D 24 Hour	Torbid	Rebetol	
Combunox	Tovaza	Retapax	
Copegus	Meclizine/Hamate Sodium	Rimicade	
Cymbalta	Mobic	Rhinaccon Aqua	
Dolomanine	Nisarel	Ritalin LA	
Dorvan-N	Nefazodone HCl	Serratio HCl	
Detrol	Nimotop	Sonata	
Detrol LA	Norditropin	Spectacef	
Rx PA Appeals			
Rx PA Medical Reviews	0	0	
Inpatient Days			
ER visits	213,013	195,568	8.9%
ER visits	134,185	144,075	-6.9%
Physician Visits			
Physicians w/25+ Patients	797,259	777,612	2.5%
Physicians w/50+ Patients	4,421	4,371	1.1%
Physicians w/100+ Patients	3,367	3,326	1.2%
Specialist Visits	6,232	7,661	-18.7%

SCR 54 TRACKING

SPY 2008 - Quarter 3 (October - December 2007)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	1,000,550	1,011,097	-1.0%
	952,665	932,520	2.2%
Total Scripts Paid	2,571,849	2,458,967	4.6%
Total Scripts Paid with PA	83,018	91,309	-8.5%
Rx PA Requests Denied	13	0	
Medications			
Abilify	Coreg CR	Lovaza	Ranidol
Ability Dismett	Cymbalta	Mesalamine Sodium	Razadyne
Accutane	Dalmane	Metenamic Acid	Razadyne ER
Aciphex	Darvon-N	Menox	Rebetol
Actiq	Dextrof	Micardis	Relaps
Alomast	Dextrof LA	Mosapril HCL	Remicade
Allegra	Diltiazel	Mosapril Hydrochlorothiazide	Rhinocort Aqua
Allegra Sud	Ditropan XL	Nasarel	Ritalin LA
Allegra-D 12 Hour	Duoneb	Nefazodone HCL	Sermatine HCL
Allegra-D 24 Hour	Ersom	Nordrapin	Sonata
Alacril	Epojen	Nordripcin Nordflex	Sparanox
Alamidex	Erfaco	Noxafil	Strattera
Atropen	Estradiol	Nutropin	Suprax
Ambien	Evista	Omactar	Symbax
Antara	Exelderm	Omeprazole	Tekturna
Antermet	Exubera Comb Pack 12	Omnicef	Teveten
Apidea	Exubera Kit	Omnitrope	Ticlid
Arthrotec 50	Exubera Patient Pack	Opona	Ticlopidine HCL
Arthrotec 75	Factive	Opona ER	Triglide
Aztreonex	Fazaclo	Opivo	Ultram ER
Azucard	Fenofibrate	Oxatet	Uniretic
Azucard HCl	Fentanyl	Oxycodeone HCL	Univasc
Augmentin XR	Fenflora	Oxycontin	VFEND
Avizta	Fexofenadine HCL	Pantac DC	Welchol
Averi	Furazepam HCL	Paril CR	Wellbutrin XL
Azilect	Futicasone Propionate	Penlac	Zolatan
Bacanase AQ	Furodot	Perfasa	Zoldlar
Baxin XL	Forsteo	Pezova	Zogelid
Bentiva	Fortical	Ponstel	Zaflo
Caduet	Frova	Prandin	Zmax
Cardene SR	Giltulvin Tablet	Provachol	Zofran
Children's Claritin	Humolope	Prostaglandin Sodium	Zofran ODT
Children's Claritin	Innepipon XL	Prevacid Napropac	Zomig
Clorox Ointment	Istatol	Priosec	Zomig ZM
Cipro HC	Itraconazole	Prism	Zymar
Cipro Suspension	Kefak	Protonix	Zyprexa
Cipro XR	Kytril	Provigil	Zypressa Zydus
Clarimax Relefobs	Lomotil	Prozac Weekly	Zytac
Clarimax Tab	Levoquin	Pulmicort	Zytac Chew Tabs
Claritin-D 12 Hour	Lokto	Pulmicort Flexhaler	Zytac Syrup
Claritin-D 24 Hour	Liptor	Pulmicort Respules	Zytac-D
Combunox	Loprox	Pulmicort Turbuhaler	
Comfan	Loprox Shampoo	Quibin	Total Drugs: 172
Rx PA Appeals	0	0	
Rx PA Medical Reviews	0	0	
Inpatient Days	225,321	215,219	4.7%
ER Visits	160,325	152,848	4.9%
Physician Visits	887,568	891,214	-0.4%
Physicians w/25+ Patients	4,548	4,405	3.2%
Physicians w/50+ Patients	3,466	3,322	4.3%
Specialist Visits	6,446	7,299	-11.7%

SCR 54 TRACKING

SFY 2008 - Quarter 3 (January - March 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	1,019,866	971,374	+5.0%
Total Scripts Pd/Pt	963,006	922,657	+4.4%
Total Scripts Pd/Pt with PA	2,660,427	2,583,646	+3.0%
Total Rx PA Requests Denied	71,896	93,715	-23.3%
In Rx PA Requests Denied	9	0	
Medications			
Abilify	Copagus	Nefazodone HCl	Taveten
Abilify Discmell	Coreg CR	Norditropin	Ticlid
Accutab	Cymbalta	Norditropin Norditrex	Ticlopidine HCl
Aconin	Dolmethe	Noxipril	Triglide
Aciphex	Desoxyn	Omecar	Utram ER
Aciso	Dextro	Omeprazole	Uniretic
Actional with Calcium	Dextro LA	Ornipsel	Univasc
Alomend	Didronal	Opono	VFEND
Allegra	Diltrophan XL	Opono ER	Welchol
Allegra Susp	Doral	Opivar	Wellbutrin XL
Allegra-D 12 Hour	Dupreb	Orenda	Xolatan
Allegra-D 24 Hour	Emanon	Oxitot	Zaditor
Alomil	Epogen	Oxycodeone HCl	Zegrid
Alomide	Friacazo	Oxycodeone HCl-Ibuprofen	Zetia
Alupent	Eszazolam	Oxycontin	Zmax
Ambien	Etiloracetate Disodium	Pantac DC	Zofran
AmesMve	Eviato	Pantoprazole Sodium	Zofran ODT
Ancobon	Euderm	Posti CR	Zomig
Antara	Factive	Penlac	Zomig ZMT
Antezem	Fazoclo	Pentasa	Zytlo
Apidra	Fenofibrate	Perevo	Zymar
Arthrotec 50	Fentanyl	Ponstel	Zyprexa
Asthrotec 75	Fentora	Prianda	Zyprexa Zydus
Artemaris	Flexofenadine HCl	Provachol	Zyrelc
Atacand	Flucizepom HCL	Pravastatin Sodium	Zyrelc Chew Tabs
Atacand HCl	Fluticasone Propionate	Prevacid Naprapac	Zyrelc Syrup
Augmentin XR	Foract	Prilosec	Zyntec-D
Avitaz	Forato	Protonix	
Axer	Fortical	Provigil	Total Drugs = 171
Azlect	Frova	Prozac Weekly	
Becanoma AQ	Giffulvin Tablet	Pulmicort	
Biotin XL	Humatene	Pulmicort Flexhaler	
Boniva	Inmoran XI	Pulmicort Respules	
Caduet	Iquix	Pulmicort Turbuhaler	
Cordura XL	Itacanazole	Quixin	
Cetilizine HCl	Ketek	Ranidol	
Childrens Claritin	Kytril	Razodyne	
Ciclosporin	Levagquin	Razodyne ER	
Cloxon Ointment	Valdo	Relpax	
Clopo NC	Lopax	Remicade	
Cipro Suspension	Lopax Shampoo	Rhinocort Aqua	
Cipro XR	Lovaza	Rhinolin LA	
Claritin Releas tabs	Meclofenamate Sodium	Sonata	
Claritin tab	Methenamic Acid	Sporanox	
Claritin-D 12 Hour	Mentax	Strattera	
Claritin-D 24 Hour	Moxiflox HCl	Suprax	
Combunox	Moxiflox-Hydrochlorothiazide	Symbrys	
Conilar	Nasarel	Tekturna	
In Rx PA Appeals	0	0	
In Rx PA Medical Review	1		
Inpatient Days	224,745	229,892	-2.2%
ER visits	176,078	167,021	+5.4%
Physician Visits	931,684	902,670	+2.6%
Physicians w/25+ Patients	4,538	4,402	+3.1%
Physicians w/50+ Patients	3,466	3,376	+2.7%
Specialist Visits	6,401	6,707	-4.6%

SCR 54 TRACKING

SFY 2008 - Quarter 4 (April - June 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	1,032,750	978,472	5.5%
Total Script Paid	1,002,136	939,536	6.7%
Total Scripts Paid with PA	2,662,965	2,420,370	10.0%
Rx PA Requests Denied	79,970	102,453	-21.9%
	13	0	

Medications

Ability	Clothes Rapideabs	Goflysin V Tabler	Prevacid Naprapac	Zomig
Ability Discinell	Claritin Syrup	Humatropo	Pilase	Zegret
Accubob	Claritin Tab	Innogen XL	Prquin XR	Zello
Accupril	Claritin-D 12 Hour	Iqu	Prosm	Zmax
Accutistic	Claritin-D 24 Hour	Itaconazole	Protonix	Zocor
Actones	Comtan	Kytril	Provigil	Zofran
Actis	Coreg CR	Lavagutin	Prozac Weekly	Zoton ODT
Advicor	Crestor	Udo	Pulmicort	Zomig
Alamos	Cymbalta	Upalen	Pulmicort Flexhaler	Zomig ZMF
Allegra	Dalmane	Loprin Gel	Pulmicort Respules	Zytlo
Allegra ODT	Dantrol	Loprin Shampoo	Pulmicort Turbuhaler	Zymar
Allegra-D 12 Hour	Dantrolene Sodium	Lovaza	Quinapril HCl	Zyprexa
Allegra-D 24 Hour	Darvont-N	Mavalt	Quinapril Hydrochlorothiazide	Zyprexa Zydus
Ancril	Deltol	Maxalt MLI	Quinaretic	Zyrtec
Amiodide	Dextro LA	Melentamic Acid	Quixin	Zyrtec Chew Tabs
Atoprev	Diflomet	Merflax	Ranidol	Zyrtec Syrup
Alupent	Ditropan XL	Metaproterenol Sulfate	Razadyne	Zyrtec-D
Ambien CR	Doral	Moxonpril HCl	Razadyne ER	
Amoxyc	Duoneb	Moxonpril-Hydrochlorothiazide	Refax	
Aniviz	Duragasic	Monopril	Rennicade	Total Drugs = 212
Anfaro	Epopen	Monopril HCT	Rhinocort Aquia	
Ansermel	Etozox	Noroxin	Ritalin LA	
Apidea	Esterazolam	Nefazodone HCl	Semprex-O	
Arthrotec	Evista	Neo-tradlin	Simvastatin	
Arthrotec 50	Exelderm	Neomycin Sulfate	Skeletal	
Arthrotec 75	Eveton	Norflex	Soma	
Asmanex	Estinca	Omeprazole	Sonata	
Alocand	Factive	Ornidol	Sparanox	
Alocand HCT	Fazaclo	Opona	Strattera	
Augmentin XR	Fenofibrate	Opona ER	Suprax	
Avizta	Fenoglide	Ophir	Symbax	
Aved	Fentanyl	Oranida	Tarka	
Azactab	Fentanyl Citrate	Orphenadrine Citrate	Tekturna	
Bactrobac	Fentora	Oxital	Teveten	
Beconase AQ	Fenmid	Oxybutynin Chloride ER	Tild	
Bicasin XL	Fexofenadine HCl	Oxycodone HCl	Tickipidikle HCl	
Boniva	Flagyl ER	Oxygenin	Triglide	
Brovona	Fluazepam HCl	Pantol DC	Ultrom ER	
Coduel	Fluticasone Propionate	Pantoprazole Sodium	Uniretic	
Cetizine HCl	Foradil	Paul CR	Univasc	
Childrens Claritin	Forteo	Pentac	Veramyst	
Claritin	Fortical	Pentasa	VFEND	
Claritin Dirl	Fosinopril Sodium	Perfomist	Welchol	
Claritin Ointment	Fosinopril-Hydrochlorothiazide	Pezava	Wellbutrin XL	
Cipro HC	Forenal	Ponsol	Xokatan	
Cipro Suspension	Frava	Prondin	Xanax	
Cipro XR	Genotropin	Provastatin Sodium	Xyzal	
Clofaz	Geodon		Zoditor	

Rx PA Appeals	0	0	
Rx PA Medical Reviews	1		
Inpatient Days	242,263	220,852	8.6%
ER visits	173,985	155,503	11.9%
Physician Visits	929,631	891,973	4.2%
Physicians w/75+ Patients	5,332	4,761	12.0%
Physicians w/50+ Patients	4,248	3,745	13.4%
Specialist Visits	6,700	6,810	-1.6%

SCR 54 TRACKING

SFY 2009 - Quarter 2 (July - September 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligible Recipients	1,047,733	1,001,411	+4.0%	
Total Scripts Paid	998,842	920,734	+8.5%	
Total Scripts Paid with PA	2,343,132	2,184,857	+7.2%	
Rx PA Requests Denied	69,392	77,932	-11.0%	
Medications	3			
Abilify	Claritin RedTabs	Citifluvin V Tablet	Prevacid Nopropac	Zantac
Ability Dismet	Claritin Syrup	Humatope	Pridsec	Zegret
Accutane	Claritin Tab	Innophen XL	Proguan XR	Zefia
Accupril	Clarinex-D 12 Hour	Iquix	Prasone	Zmax
Acyclovic	Clarinex-D 24 Hour	Itaconazole	Pristone	Zocor
Aciphex	Cortizan	Kytril	Provigil	Zohar
Actiq	Coret CR	Levoquin	Prozac Weekly	Zohar ODT
Adcote	Crestor	Udcida	Pulmicort	Zomig
Alaris	Cymbalta	Upafen	Pulmicort Flexhaler	Zomig ZMT
Allegra	Dalmane	Lopax Gel	Pulmicort Respules	Zylo
Allegra ODT	Dantrolum	Lopax Shampoo	Pulmicort Turbulizer	Zymox
Allegra-D 12 Hour	Dantrolene Sodium	Lovaza	Quinapril HCL	Zyprexa
Allegra-D 24 Hour	Darvan-N	Mavent	Quinapril-Hydrochlorothiazide	Zyprexa Zydis
Alocril	Detrol	Moxatril ML	Quinavate	Zytec
Alomide	Detrol LA	Methemoglobin Acid	Quixin	Zytec Chew Tabs
Altoprev	Diltiazel	Mentax	Ranidex	Zytec Syrup
Alupent	Ditropan XL	Metaproterenol Sulfate	Razadryne	Zytec-D
Ambien CR	Doral	Moxipril HCL	Razadryne ER	
Amerge	Duroneb	Moxipril-Hydrochlorothiazide	Repos	
Amtra	Durogesic	Monopril	Remicade	Total Drugs = 197
Antara	Epogen	Monopril HCT	Rhinocort Aqua	
Arzomet	Enacea	Nasozal	Ritalin LA	
Apidra	Estrazolam	Neoadone HCL	Sempres-D	
Antro	Evera	Neo-Fradin	Simwastatin	
Arthrotec 50	Exelderm	Neomycin Sulfate	Skeletal	
Arthrotec 75	Exelon	Norflex	Soma	
Asmetex	Extina	Omacor	Sonata	
Atecand	Fachive	Omeprazole	Sporanox	
Atecand HCT	Fazaclo	Ornaref	Strafero	
Augmentin XR	Fencitabrate	Opana	Suprax	
Avizta	Fenoglide	Opana ER	Symbax	
Axert	Fentanyl	Opiflur	Tarka	
Azactile	Fentanyl Citrate	Orencia	Tekturna	
Baclofen	Fentora	Orphenadrine Citrate	Teveten	
Baclofen AD	Flexmid	Osistot	Ticlid	
Biaxin XL	Fexofenadine HCL	Oxybutynin Chloride ER	Ticlopidine HCL	
Boniva	Fogyl ER	Oxycodeone HCL	Triglide	
Brovana	Furazepam HCL	Oxycontin	Ultron ER	
Caduet	Futicasone Propionate	Panlor DC	Unisetic	
Cetirizine HCL	Foradil	Pantoprazole Sodium	Unisosc	
Children Cetirizine	Forteo	Passil CR	Veramyst	
Clova	Fortical	Pentac	VFEND	
Clova Oint	Fosinopril Sodium	Pentasa	Welchol	
Clovia Ointment	Fosinopril-Hydrochlorothiazide	Perforomist	Wellbutrin XL	
CitraHC	Fosrenol	Pexeva	Xolotan	
Cipro Suspension	Frova	Ponstel	Xanax	
Cipro XR	Genotropin	Priandin	Xyzal	
Clarhex	Geodon	Pravastatin Sodium	Zaditor	
Rx PA Applied	0	0		
Rx PA Medical Reviews	1			
Inpatient Days	215,600	213,013	+1.2%	
ER visits	165,214	134,185	+23.1%	
Physician Visits	823,349	797,259	+3.3%	
Physicians w/25+ Patients	5,144	4,421	+16.4%	
Physicians w/50+ Patients	4,046	3,307	+20.2%	
Specialist Visits	6,515	6,232	+4.5%	

SCR 54 TRACKING

SFY 2009 - Quarter 3 (October - December 2008)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Eligible Recipients	1,096,999 990,441	1,046,177 952,663	4.7% 4.6%
Total Scripts Pd	2,634,217	2,571,849	2.4%
Total Scripts Pd wth PA	80,015	83,618	-4.3%
Rx PA Requests Denied	10	0	

Medications

Ability	Claritin RediTabs	Grilukit V Tablets	Premocid Napropac	Zanaflex
Ability Discmell	Claritin Syrup	Humulope	Prilosec	Zegerid
Accupunc	Claritin Tab	Innoven XL	Proquin XR	Zetia
Accupril	Claritin-D 12 Hour	Iaxix	Prisom	Zmax
Accuteric	Claritin-D 24 Hour	Itraconazole	Protonix	Zocor
Aciphex	Comtan	Kytril	Provigil	Zofran
Actiq	Coreg CR	Levaquin	Prozac Weekly	Zoton ODT
Advair	Crestor	Lialda	Pulmicort	Zomig
Almosat	Cymbalta	Loaten	Pulmicort Flexhaler	Zomig ZMT
Allegra	Daklinza	Lopar Gel	Pulmicort Respules	Zyflo
Allegra ODT	Dantrium	Lopar Shampoo	Pulmicort Turbuhaler	Zymox
Allegra -D 12 Hour	Dantrolene Sodium	Lovastec	Quinapril HCL	Zyprexa
Allegra -D 24 Hour	Darvocet-N	Mavall	Quinapril-Hydrochlorothiazide	Zyprexa Zydus
Alocit	Dextro	Maxalt MLI	Glukonate	Zytac
Alomide	Dextro UA	Melatonin Acid	Quixin	Zytac Chew Tabs
Altopen	Diclofenac	Menoxaz	Ranidol	Zytac Syrup
Alupent	Ditropan XL	Meprobamate Sulfate	Razadyme	Zytac-D
Ambien CR	Doral	Mexipir HCL	Razadyme ER	
Amerge	Duoneb	Mexipir-Hydrochlorothiazide	Relpax	
Amix	Duragesic	Monopril	Remicade	Total Drugs = 260
Antara	Epopos	Monopril HCL	Rhinocort Aqua	
Anzemet	Erlacto	Natrel	Ritalin LA	
Acidra	Etrizolam	Neftazodone HCL	Sempre-D	
Aridia	Evista	Neo-Froxin	Simwastatin	
Arthrotec 50	Exelderm	Neomycin Sulfate	Skelaxin	
Arthrotec 75	Exelon	Noflex	Soma	
Armonex	Exina	Oncotac	Sondia	
Alacand	Faciote	Omepracazole	Sporanox	
Alacand HCL	Faxotac	Ornidol	Strattera	
Augmentin XR	Fenofibrate	Opadra	Suprox	
Avritta	Fenoflide	Opadra ER	Symbax	
Axert	Fentanyl	Optikor	Takro	
Azette	Fentanyl Citrate	Okendia	Tekturna	
Bactroban	Fentora	Orphenadrine Citrate	TeVeten	
Becontate AQ	Fenmid	Oxitol	Ticlid	
Blain XL	Fexofenadine HCL	Chrybutynin Chloride ER	Triclopidine HCL	
Boniva	Flugyl ER	Oxycodone HCL	Triglide	
Brovana	Flurazepam HCL	Oxycontin	Urtum ER	
Coduef	Fluticasone Propionate	Parlor DC	Uniretic	
Cetilistine HCL	Fordol	Pantoprazole Sodium	Univasc	
Children Cetilin	Forteo	Paul CR	Veramyst	
Clozan	Fortical	Peniac	VFEND	
Clozan Ointl	Fosinopril Sodium	Pentasa	Welchol	
Clozan Ointment	Fosinopril-Hydrochlorothiazide	Pertacard	Wellbutrin XL	
Clopo NC	Fosrenol	Pexeva	Xolatol	
Closp Suspension	Frova	Ponsol	Xifaxan	
Closp XR	Genotropin	Prondin	Xyzal	
Clothes	Geodon	Provastatin Sodium	Zoditor	

Rx PA Appeals	0	0	
Rx PA Medical Reviews	0	0	
Inpatient Days	228,356	225,321	1.3%
ER visits	150,584	160,325	-6.1%
Physician Visits	955,234	887,568	7.6%
Physicians w/25+ Patients	4,796	4,548	5.5%
Physicians w/50+ Patients	3,694	3,466	6.6%
Specialist Visits	4,836	4,446	1.4%

SCR 54 TRACKING

SFY 2009 - Quarter 3 (January - March 2009)

Information Category	Current Quarter	Previous Year Quarter	Percent Change
Regions Recipients	1,116,651 1,012,418	1,085,879 963,008	4.8% 5.1%
Total Scripts Paid	2,827,636	2,660,427	6.3%
Total Scripts Paid with PA	86,278	71,896	20.0%
Rx PA Requests Denied	0	0	

Medications

Abilify	Cipro HC	Fenofibrate	Ocuflox	Stelazin
Ability Discreet	Cipro Suspension	Fenoglide	Oflazacin	Soma
Accutane Low Dose	Cipro xP	Fenofenyl Citrate	Olux-E	Sonata
Aciphex	Ciprofloxacin ER	Fezmid	Olux-Olux-E	Spectracef
Actavis	Ciprofloxacin HCl	Hogyl Er	Omacar	Sparaxas
Aclix	Claritin RedTabs	Rector	omeprazole	Strattera
Advar	Claritin Syrup	Flonase	Omniais	Symbax
Albuterol Sulfate Low Dose	Claritin Tab	Runtsolice	Opana	Tarka
Alcaine Metacaine Dipropionate	Claritin-D 12 Hour	Flurazepam HCl	Opana ER	Tekturna
Allergo COT	Claritin-D 24 Hour	Fluticasone Propionate	Orenda	Tevehan
Allergo-D 12 Hour	Clarithromycin	Forteo	Orphenadrine Citrate	Tevenan HCl
Allergo-D 24 Hour	Clarithromycin ER	Fosamax	Oxitrol	Tiaffid
Amantadine	Clobex	Fosamax Plus D	Oxybutynin Chloride ER	Ticlopidine HCl
Atorvast	Clofazim	Fosfomax	Oxycodeone HCl	Topicort
Amigan CR	Comtan	Frova	Oxycontin	Topicort LP
Anchinate	Cordran	Genotropin	Pancerecarb MS-16	Tiglide
Amerge	Catog CR	Glytazone HCl	Pancerecarb MS-4	Ultram ER
Amesive	Crestor	Glibenclam HCL	Pancerecarb MS-8	Uniferic
Amis	Cromolyn Sodium	Hafog	Panlio DC	Univasc
Androgyne	Cutivate	Humatrop	Pantoprazole Sodium	Vancocin HCl
Antara	Cymbalta	Innopran XL	Paroxetine HCL	Vanos
Anhimer	Dantrolum	Irvegra	Paxil CR	Vantin
Apidra	Dantrolene Sodium	Ipratropium-Albuterol	Periac	Verlafosine HCl
Arthria	Darvon-N	Itraconazole	Pentasa	Verdesa
Arthrotec 50	Dermotop	Kytril	Perforomist	VFEND
Arthrotec 75	Desonate	Lomistil Granules	Pontal	Vusion
Asmonex	Desoximetasone	Levoquin	Pronatin	Welchol
Azacand	Deltol	Lialda	Prednicarbate	Wellbutrin XL
Alocon HC1	Diltiazel	Unidose	Prevacid Naprapac	Xanax
Avista	Diltiazene Diacetate	Iuprofen	Priosec	Xyzal
Avert	Dipentum	Laprox Shampoo	Pristiq	Zanaflex
Atrofie	Ditropan XL	Lavaza	Proquin XR	Zegerid
Atect	Duoden	Lumigan	Protonix	Zetka
Bactroban	Duogistic	Luvox CR	Provigil	Zomig
Becanazole AQ	Econazole Nitrate	Mazoff	Pratoc Weekly	Zomig Zmt
Blauin	Effexor	Maxell MLT	Psoron	Zovia
Blauin XL	Elocon	Meclofenamate Sodium	Pulmicort	Zyrtec CR
Brevana	Emcor	Metenamic Acid	Pulmicort Respules	Zyprexa
Budeplan XL	Epogen	Mentax	Quibin	Zyprexa Zydis
Bupropion XL	Erfaco	Moxipir HCL	Razadyne	Zyrtec
Systolic	Estrazolam	Moxipir-Hydrochlorothiazide	Razadyne ER	Zytec (Legend)
Caduveo	Evista	Mometasone Furoate	Remicade	Zytec-D
Cardura XL	Exederm	Nabumetone	Renuva	Zytec-D (Legend)
Cetopodizime Proxim	Eksion	Nasarel	Rhinocort Aqu	
Chlorhex Claritin	Exelon Patch	Nefazodone HCL	Ritalin LA	Total Drugs = 236
Clospipra	Evina	Neomycin Sulfate	Semporex-D	
Clavon	Factive	Nortek	Seroquel XR	
Clavon Oint	Fazoclo	Noxofill	Seroftim	

Rx PA Appeals	0	0
Rx PA Medical Reviews	0	0
Inpatient Days	238,532	224,745
ER visits	168,832	176,078
Physician Visits	986,440	931,666
Physicians w/25+ Patients	4,917	4,538
Physicians w/50+ Patients	3,759	3,466
Specialist Visits	6,614	6,401
		3.3%

SCR 54 TRACKING

SPY 2009 - Quarter 4 (April - June 2009)

Information Category	Current Quarter	Previous Year Quarter	Percent Change		
Enquiries	1,118,700	1,078,622	3.7%		
Recipients	1,004,215	1,002,136	2.2%		
Total Scripts Paid	2,532,276	2,662,985	-4.9%		
Total Scripts Paid with PA	92,979	79,973	16.3%		
Rx PA Requests Denied	13	0			
Medications					
Abilify	Clocaium Acetate	Emadine	Loprox Shampoo	Prinidin	Venlafax
Abilify Discmelt	Cordizem LA	Enalstav	Lotrel	Prednicarbate	Verelan PM
Accutane	Cetpodoxime Proxetil	Epoegen	Lovaza	Prevacid Naprapac	VFEND
Accutane Low Dose	Cetiztizine HCL	Ertaczo	Lumigan	Prevacac	Vytorin
Aciphex	Children Clothin	Etrazolam	Lunesta	Prlsoc	Welchol
Actavis	Clozaplor	Evtia	Luvox CR	Prltla	Xifaxan
Actonel with Calcium	Ciloxan	Exederm	Mazoll	Proquin XR	Zomig
Advair	Clozxin Oint	Eteilon	Maxell MRI	Protonix	Zomig ZM
Afamast	Climzia	Exelon Patch	Medofenamate Sodium	Provogil	Zyrtec
Albuterol Sulfate	Cipro	Entiza	Mentax	Prazac Weekly	Zyrtec-D
Albuterol Sulfate Low Dose	Cipro HC	Factive	Moexipril HCL	Pulmicort	Zylo CR
Alfentanil Sulfate Dipropionate	Cipro Suspension	Fenobiprole	Moexipril-Hydrochlorothiazide	Pulmicort Respules	Zylo CR
Algeo	Cipro XR	Fenugide	Mometasone Furoate	Pylera	Zylo CR
Allegro ODT	Ciprofloxacin HCL	Fentanyl	Nabumetone	Quixin	Zylo CR
Allegro Susp	Claritin RediTabs	Fentanyl Citrate	Nasarel	Razadyme	Zyrtec
Allegro-D 12 Hour	Claritin Syrup	Fentora	Netazosadene HCL	Rimicodine	Zyrtec-D
Allegro-D 24 Hour	Claritin Tab	Fexmid	Nisoldipine	Renuva	Total Drugs = 261
Alomide	Claritin-D 12 Hour	Fexofenadine HCL	Norflex	Requip XL	
Alvesco	Claritin-D 24 Hour	Flagyl ER	Ocuclus	Rhinocod Acqua	
Ambien Cr	Clarithromycin	Flektor	Orloxicad	Ritalin LA	
Amoxicillide	Clarithromycin ER	Flianase	Otr-E	Rozarem	
Amoxiga	Clobes	Fumigadole	Otr-Otr-E	Sotzen	
Amoxiga	Cloderm	Furazepam HCL	Omcocar	Sanctura	
Amoxia	CNL 8	Furicosamide Propionate	Omepazazole	Sanctura XR	
Androgel	Cardion	Fomeo	Omoris	Soncuso	
Antara	Cereq CR	Fosamax	Opana	Sompre-D	
Antarmel	Covera-HS	Fosamax Plus D	Opana ER	Seroquel XL	
Apericon	Crestor	Frova	Orencia	Skeletin	
Apicea	Cromatyn Sodium	Glitulin V	Orphenadrine Citrate	Soma	
Arktra	Cultivate	Glitulin V Tabler	Orphenadrine Compound	Sonata	
Arthrotec 50	Cymbalta	Halog	Orphenadrine Compound Forte	Spectacef	
Arthrotec 75	Dantrolene	Humatope	Orphenadrine Forte	Sparanox	
Ametriptol	Dantrolene Sodium	Imitrex	Oxitol	Shoffera	
Atacand	Darvan-N	Imitrex ER	Oxybutynin Chloride ER	Symbax	
Atacand HCl	Dermatop	Imitrex Injection	Oxycodeone HCL	Tekturna	
Avitraz	Desonate	Imitrex Nasal Spray	Oxycontin	Tekturna HCL	
Avent	Desoximetasone	Imitrex Tablets	Pancarecarb MS-16	Topikort	
Azaflor	Desoxyn	Invegu	Pancarecarb MS-4	Topilon LP	
Baconase AQ	Dextrol	Ibuprofum-Albuterol	Pancarecarb MS-8	Troclear	
Betaadol HCL	Dicromel	Itraconazole	Panlor DC	Triglide	
Biotin	Diflucane Disacetate	Kytril	Pantoprazole Sodium	Ultram ER	
Biostin XL	Diltropon XL	Lamisil Granules	Paracetamol HCL	Uniretic	
Broward	Duoneb	Levaquin	Paul CR	Univasc	
Budeption XL	Durogesic	Lidoo	Penlac	Vanax	
Budesonide	Econazole Nitrate	Undone	Pentasa	Vanthin	
Bupropion XL	Iffexor	Upafen	Perforomist	Venlafaxine HCL	
Bytolic	Elphos	Lofibra	Ponstel	Venlafaxine HCL ER	
Coduef	Elecon	Torprox	Prinidin	Vertopamil ER	
Rx PA Appeals	0	0			
Rx PA Medical Reviews	2	0			
Inpatient Days					
ER Visits	235,000	240,263	-2.2%		
	168,998	173,985	-2.9%		
Physician Visits	941,042	929,631	1.2%		
Physicians w/25+ Patients	5,006	5,332	-6.1%		
Physicians w/50+ Patients	3,672	4,248	-8.9%		
Specialist Visits	6,659	6,700	-0.6%		

SCR 54 TRACKING

SEY 2010 - Quarter 4 (July - September 2009)

Information Category	Current Status	Previous Year Quarter	Percent Change	
Eligible Recipients	1,141,692 1,036,315	1,096,119 998,842	4.2% 3.8%	
Total Scripts Paid	2,600,767	2,343,132	13.6%	
Total Scripts Paid with PA	96,026	69,392	38.4%	
Rx PA Requests Denied	11	0		
Medications				
Abilify	Catamarcate	Emendine	Lopizor Shampoo	Prondin
Ability Discreet	Cardizem LA	Enavate	Tolrel	Prednicarbate
Accutane	Cefpodoxime Pravelt	Epojen	Tovara	Prevacid Napropac
Accutane Low Dose	Ceftriaxone HCL	Ertracaz	Lumigan	Prevpac
Acephex	Children Claritin	Estazolam	Lunesta	PriLOSEC
Advil	Clofibrate	E Vista	Luxor CR	PriLeq
Actonel with Calcium	Clozoxan	Exiderm	Maxalt	Procaquin XR
Advicor	Claron Oint	Exelon	Maxalt M/T	Protona
Alomast	Cimeta	Exelon Patch	Meclofenamate Sodium	Provogli
Albuterol Sulfate	Cipro	Exina	Mentax	Prazac Weekly
Albuterol Sulfate Low Dose	Cipro HC	Factive	Moexipril HCl	Pulmicort
Alclometasone Dipropionate	Cipro Suspension	Fenofibrate	Moexipril-Hydrochlorothiazide	Pulmicort Rescues
Allergia	Cipro XR	Fenoglide	Mometasone Furoate	Pyleto
Allergic CDT	Clofibrate HCL	Fentanyl	Nabumetone	Quish
Allergie Susp	Clotrimazole Rediflote	Fentanyl Citrate	Nasarel	Razodyne
Allergie-D 12 Hour	Clotrimox Syrup	Fentora	Neferazodone HCl	Remicade
Allergie-D 24 Hour	Clotrimex Tab	Fexmid	Nitoldipine	Renugra
Alomide	Clotrimex-D 12 Hour	Fexofenadine HCL	Noftin	Requip XL
Alvaca	Clotrimex-D 24 Hour	Foxy ER	Ocular	Rhinocort Aqua
Amblen Cr	Clotrimoxynol	Flecto	Oflloxacin	Risolt LA
Amchonium	Clotrimoxynol ER	Flonase	Olu-E	Roxaren
Amerge	Clobex	Flunisolide	Olu-Olu-E	Satzen
Amoxys	Cloper	Flurazepam HCL	Omacor	Santura
Amrik	CNLS	Fluticasone Propionate	Ormeprazole	Sancuso XR
Androgel	Cordian	Forteo	Onnaris	Sancuso
Antara	Coreg CP	Fosamax	Opanda	Samples-D
Anaxetmel	Covera-HS	Fosamax Plus D	Opando ER	Seroquel XR
Apesicon	Crestor	Frova	Oracida	Steloxan
Apidea	Cromolyn Sodium	Giflutin V	Orphenadrine Citrate	Soma
Arbitra	Cultivate	Giflutin V Tablet	Orphenadrine Compound	Sonata
Asthrotec 60	Cymbalta	Holog	Orphenadrine Compound Forte	Spectracef
Asthrotec 75	Dantrolene	Humatapse	Orphendisic Forte	Sporanox
Astmanex	Dantrolene Sodium	Imitrex	Oxistat	Strattera
Atacand	Darvan-N	Imitrex INJ	Oxybutynin Chloride ER	Symbyax
Atacand HCT	Dermatop	Imitrex Injection	Oxycodeone HCL	Tekturna
Avitaz	Desonate	Imitrex Nasal Spray	Oxycontin	Tekturna HCL
Axent	Desoximetasone	Imitrex Tablet	Pancarecarb MS-16	Topicort
Axasite	Desoxyn	Invega	Pancarecarb MS-4	Topicort IP
Baconase AQ	Detrol	Ipratropium-Albuterol	Pancarecarb MS-8	Tracleer
Bentropidol HCL	Didranol	Itroconazole	Panlor DC	Triglide
Biotin	Diflorasone Diacetate	Kytril	Pantoprazole Sodium	Ultram ER
Biotin XL	Ditropan XL	Lamictil Granules	Paracetamol HCL	Uniretic
Brovana	Duaneb	Levoquin	Paraxil CR	Univasc
Budeprion XL	Duragistic	Udozo	Perlac	Vancos
Budesonide	Econazole Nitrate	Undone	Perlosa	Vantin
Buproprion XL	Effexor	Uprofen	Perornatol	Venlafaxine HCL
Bystolic	Elphos	Lofibru	Ponstel	Venlafaxine HCL ER
Caduet	Eloton	Lorpraz	Prandin	Verapamil ER
Rx PA Appeals	0	0		
Rx PA Medical Reviews	0	0		
Inpatient Days	225,209	215,606	4.5%	
ER Visits	172,538	165,214	4.4%	
Physician Visits	934,081	823,349	13.4%	
Physicians w/25+ Patients	5,029	5,144	-2.2%	
Physicians w/50+ Patients	3,364	4,046	-4.0%	
Specialist Visits	6,618	6,515	1.6%	

SCR 54 TRACKING

SFY 2010 - Quarter 2 (October - December 2009)

Information Category	Current Quarter	Previous Year Quarter	Percent Change	
Eligible Recipients	1,153,049	1,108,311	4.2%	
Eligible Recipients	1,091,391	996,441	5.4%	
Total Scripts Pd/P	2,289,047	2,634,217	-5.0%	
Total Scripts Pd/P with PA	118,814	89,015	48.5%	
Rx PA Requests Denied	16	0		
Medications				
Abilify	Cordarone XL	Duoneb	Itraconazole	Opana
Ability Discreet	Cefdinir	Duravol	Kapidex	Opana ER
Accutab	Cefpodoxime Proxetil	Econazole Nitrate	Kinect	Oplivar
Accutane Low Dose	Celebrex	Effexor	Kytril	Oracea
Aciphex	Cosaserf	Effexor XR	Lamisil	Orencia
Actiq	Cetirizine HCL	Elestat	Lamivudine Granules	Orphenadrine Citrate
Acular	Childrens Clotrim	Eliges	Levaquin	Orphenadrine Compound
Acular LS	Octapost	Emend	Lidoda	Orphenadrine Compound Forte
Advair	Clozaril	Enablex	Undone	Orphenegesic
Albuterol Sulfate	Clozan Oint	Epopen	Upalen	Orphenegesic forte
Albuterol Sulfate Low Dose	Cimzia	Erlacto	Locard Lipocream	Ostrial
Allergia	Cipro	Eszatol	Lopros	Oxybutynin Chloride ER
Allergia ODT	Cipro Suspension	Etidronate Disodium	Loratad	Oxycodeone HCL
Allergia Sup	Cipro XR	E visto	Loraz	Oxycontin
Allergo-D 12 Hour	Ciprofloxacin ER	Exelderm	Lumigan	Pancuronium MS-16
Allergo-D 24 Hour	Ciprofloxacin HCL	Exelon	Lunesta	Pantacur DC
Allocc	Claritin	Exitha	Luvas CR	Pantoprazole Sodium
Amide	Claritin Syrup	Factive	Matathon	Paracetamol HCL
Alvesco	Clotrimax Tab	Fenofibrate	Maxilar Automotor	Patolase
Ambien Cr	Clotrimax D 12 Hour	Fenoglide	Maxill	Paxil CR
Amergen	Clotrimax D 24 Hour	Fentanyl	Marshall MLI	Perloc
Amoxi	Clotrimoxacin	Fentanyl Circles	Mentos	Pentac
Amphetamine Salt Combo	Clotrimoxacin ER	Femina	Melaproteranol Sulfate	Perloram
Antara	Cloben	Fexofenadine HCL	Micaper	Perloramist
Antiemet	Cloderm	Flagyl ER	Moxipril HCL	Pestiva
Apridio	Clozapine	Hector	Moxipril Hydrochlorothiazide	Prandimet
Apridio Solostar	CNL 8	Flonase	Mometasone Furoate	Prandit
Aptenazin	Comtan	Furosemide	Nabumetone	Preypac
Apres	Cordion	Flurazepam HCL	Nasacort AQ	Priac
Arthrotec 50	Coreg CR	Fluticasone Propionate	Nefazodone HCL	Procentra
Arthrotec 75	Clofelysin Sodium	Forsteo	Nevanac	Proguin XR
Ashantez	Cultivate	Fortical	Nisoldipine	Protonix
Aflacard	Cymbalta	Fosamax	Norflex	Provant HFA
Aflacard HCT	Dantrol	Fosamax Plus D	Novolin	Provigil
Aflurovent	Dantrolene Sodium	Frova	Novolin 70-30	Prazac
Avizta	Darvon-N	Giltutrin V	Novolin 70-30 Injlet	Prazac Weekly
Axitil	Dermatobiotic HCL	Giltutrin	Novolin N	Pulmicort
Aquatec	Desonide	Holog	Novolin N Injlet	Pulmicort Respaher
Aslect	Desoximetasone	Humalope	Novolin R	Pytera
Baclofene AG	Dextroamphetamine	Hydrocodone Butyrate	Novolog	Quixin
Biotin	Dextroamphetamine-Amphetamine	Imrex	Novolog Mix 70-30	Rapotic
Biotin XL	Diclofenac	Imrex Injection	Noxafil	Razadyme ER
Broxona	Diflucan	Imrex Nasal Spray	Ocuflx	Ramicade
Budeprion XL	Diflucan-Diacetate	Imrex Tablet	Ofoxacin	Renvela
Budesonide	Diketac-S	Invega	Olu-E	Risup XL
Buproprion XL	Ditrapan XL	Ipratropium Bromide	Omeprazole	Rhinocort Aqua
Calcium Acetate	Dorzolamide HCL	Ipratropium Albuterol	Ornare	Risperdal Consta
Cardizem LA	Dorzolamide Timolol	Iquix	Ornaref	Ritalin LA
Rx PA Appeals	0	0		Xopenex HFA
Rx PA Medical Reviews	2			Xyzal
Inpatient Days	226,111	220,356	-1.0%	Zanaflex
ER Visits	180,322	150,884	19.7%	Zegrid
Physician Visits	976,223	955,234	2.2%	Zeta
Physicians w/25+ Patients	5,166	4,796	7.7%	Zmax
Physicians w/50+ Patients	3,950	3,694	6.9%	Zomig
Specialist Visits	6,736	6,536	3.1%	Zomig ZM
				Zotac
				Zymar
				Zyprexa
				Zyprexa Zydr
				Zytec
				Zytrec-D
				Total Drugs = 308